Nuo Therapeutics (AURX) 10-K 29 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Mar. 24, 2017	Jun. 30, 2016
Document Information [Line Items]
Entity Registrant Name	Nuo Therapeutics, Inc.
Entity Central Index Key	1,091,596
Trading Symbol	nuot
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		9,927,112
Entity Public Float			$ 3.6
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 2,620,023
Restricted cash	53,503
Accounts and other receivable, net	294,298
Inventory, net	69,954
Prepaid expenses and other current assets	334,437
Total current assets	3,372,215
Property and equipment, net	486,116	$ 1,115,214
Deferred costs and other assets	278,730
Intangible assets, net	7,840,408
Goodwill	2,079,284	0
Total assets	14,056,753
Current liabilities
Accounts payable	392,615
Accrued expenses and liabilities	1,054,677	2,453,255
Accrued interest
Deferred revenue, current portion
Convertible debt subject to put rights
Total current liabilities	1,447,292
Deferred revenue
Other liabilities	123,434
Total liabilities	1,570,726
Commitments and contingencies (Note 14)
Stockholders' equity (deficit)
Common stock	993
Preferred stock	3
Additional paid-in capital	18,180,658
Accumulated deficit	(5,695,627)
Total stockholders' equity (deficit)	12,486,027
Total liabilities and stockholders' equity (deficit)	14,056,753
Predecessor [Member]
Current assets
Cash and cash equivalents		922,317
Restricted cash		53,449
Accounts and other receivable, net		1,014,245
Inventory, net		254,385
Prepaid expenses and other current assets		804,508
Total current assets		3,048,904
Property and equipment, net		1,115,214
Deferred costs and other assets		396,233
Intangible assets, net		2,513,394
Goodwill
Total assets		7,073,745
Current liabilities
Accounts payable		1,066,766
Accrued expenses and liabilities		2,453,255
Accrued interest		3,143,470
Deferred revenue, current portion		523,900
Convertible debt subject to put rights		35,000,000
Total current liabilities		42,187,391
Deferred revenue		637,097
Other liabilities		307,058
Total liabilities		43,131,546
Commitments and contingencies (Note 14)
Predecessor conditionally redeemable common stock, 909,091 shares issued and outstanding		500,000
Stockholders' equity (deficit)
Common stock		12,477
Predecessor common stock issuable		392,950
Additional paid-in capital		125,956,728
Accumulated deficit		(162,919,956)
Total stockholders' equity (deficit)		(36,557,801)
Total liabilities and stockholders' equity (deficit)		$ 7,073,745

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	31,500,000	425,000,000
Common stock, shares issued (in shares)	9,927,112	125,680,100
Common stock, shares outstanding (in shares)	9,927,112	125,680,100
Preferred stock, par value (in dollars per share)	$ 0.0001
Preferred stock, shares authorized (in shares)	1,000,000
Preferred stock, shares issued (in shares)	29,038
Preferred stock, shares outstanding (in shares)	29,038
Preferred stock, liquidation value	$ 29,038,000
Predecessor [Member]
Temporary equity, shares issued (in shares)		909,091
Temporary equity, shares outstanding (in shares)		909,091
Common stock, shares authorized (in shares)		425,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2015
Revenue
Product sales		$ 366,395
License fees
Royalties		106,050
Total revenue		472,445
Costs of revenue
Costs of sales		729,050
Costs of license fees
Costs of royalties
Total costs of revenue		729,050
Gross profit (loss)		(256,605)
Operating expenses
Sales and marketing		893,138
Research and development		1,015,871
General and administrative		3,292,348
Impairment of intangible assets and goodwill
Total operating expenses		5,201,357
Loss from operations		(5,457,962)
Other income (expense)
Interest, net		(2,219)
Write-off of debt discount and deferred issuance costs
Change in fair value of derivative liabilities
Loss on disposal of fixed assets
Other		89,105
Reorganization items, net		(324,551)
Total other income (expense)		(237,665)
Income (loss) before benefit for income taxes		(5,695,627)
Benefit for income taxes
Net income (loss)		$ (5,695,627)
Basic and diluted earnings (loss) per share
Basic (in dollars per share)		$ (0.58)
Diluted (in dollars per share)		$ (0.58)
Weighted average shares outstanding
Basic (in shares)		9,895,966
Diluted (in shares)		9,895,966
Predecessor [Member]
Revenue
Product sales	$ 922,608		$ 6,390,194
License fees	139,534		3,402,377
Royalties	670,079		1,718,406
Total revenue	1,732,221		11,510,977
Costs of revenue
Costs of sales	829,095		6,293,394
Costs of license fees			1,500,313
Costs of royalties	54,543		173,403
Total costs of revenue	883,638		7,967,110
Gross profit (loss)	848,583		3,543,867
Operating expenses
Sales and marketing	833,943		6,236,357
Research and development	554,586		2,550,805
General and administrative	2,307,009		9,021,669
Impairment of intangible assets and goodwill			27,054,517
Total operating expenses	3,695,538		44,863,348
Loss from operations	(2,846,955)		(41,319,481)
Other income (expense)
Interest, net	(252,956)		(3,772,227)
Write-off of debt discount and deferred issuance costs			(37,634,180)
Change in fair value of derivative liabilities			29,846,821
Loss on disposal of fixed assets			(6,754)
Other	2,495		(11,300)
Reorganization items, net	31,271,350
Total other income (expense)	31,020,889		(11,577,640)
Income (loss) before benefit for income taxes	28,173,934		(52,897,121)
Benefit for income taxes			(89,013)
Net income (loss)	$ 28,173,934		$ (52,808,108)
Basic and diluted earnings (loss) per share
Basic (in dollars per share)	$ 0.22		$ (0.42)
Diluted (in dollars per share)	$ 0.15		$ (0.42)
Weighted average shares outstanding
Basic (in shares)	125,951,100		125,951,100
Diluted (in shares)	193,258,792		125,951,100

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Redeemable Common Stock [Member]	Common Stock [Member]	Preferred Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (Predecessor [Member]) at Dec. 31, 2014	$ 500,000	$ 12,477	$ 0	$ 392,950	$ 125,173,973	$ (110,111,848)	$ 15,467,552
Balance (in shares) (Predecessor [Member]) at Dec. 31, 2014		125,680,100
Stock-based compensation | Predecessor [Member]					782,755		782,755
Net income (loss) | Predecessor [Member]						(52,808,108)	(52,808,108)
Balance (Predecessor [Member]) at Dec. 31, 2015	500,000	$ 12,477		392,950	125,956,728	(162,919,956)	(36,557,801)
Balance (in shares) (Predecessor [Member]) at Dec. 31, 2015		125,680,100
Stock-based compensation | Predecessor [Member]					55,081		55,081
Net income (loss) | Predecessor [Member]						28,173,934	28,173,934
Balance (Predecessor [Member]) at May. 04, 2016			0				0
Balance (in shares) (Predecessor [Member]) at May. 04, 2016		0
Elimination of Predecessor Company equity | Predecessor [Member]	$ (500,000)	$ (12,477)		$ (392,950)	(126,011,809)	134,746,022	8,328,786
Elimination of Predecessor Company equity (in shares) | Predecessor [Member]		(125,680,100)
Balance at May. 05, 2016		$ 750	$ 3		17,887,966		17,888,719
Balance (in shares) at May. 05, 2016		7,500,000	29,038
Issuance of Successor Company preferred stock (in shares)			29,038
Issuance of Successor Company preferred stock			$ 3		8,288,716		8,288,719
Issuance of Successor Company common stock (in shares)		7,500,000
Issuance of Successor Company common stock		$ 750			9,599,250		9,600,000
Balance (Predecessor [Member]) at May. 04, 2016			0				0
Balance (in shares) (Predecessor [Member]) at May. 04, 2016		0
Net income (loss)							(5,695,627)
Balance at Dec. 31, 2016		$ 993	$ 3		18,180,658	(5,695,627)	12,486,027
Balance (in shares) at Dec. 31, 2016		9,927,112	29,038
Balance at May. 05, 2016		$ 750	$ 3		17,887,966		17,888,719
Balance (in shares) at May. 05, 2016		7,500,000	29,038
Stock-based compensation			$ 0		74,999
Net income (loss)						(5,695,627)	(5,695,627)
Balance at Dec. 31, 2016		$ 993	$ 3		18,180,658	$ (5,695,627)	12,486,027
Balance (in shares) at Dec. 31, 2016		9,927,112	29,038
Issuance of Successor Company common stock (in shares)		2,264,612
Issuance of Successor Company common stock		$ 226			(226)
Issuance of common stock for services (in shares)		162,500
Issuance of common stock for services		$ 17			$ 217,919		$ 217,936

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)		$ (5,695,627)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash interest expense
Non-cash gain on reorganization
Change in fair value of derivative liabilities
Impairment of intangible assets and goodwill
Stock-based compensation		74,999
Depreciation and amortization		836,192
Non cash debtor-in-possession note payable debt issuance costs
Deferred income tax provision
Increase in allowance for doubtful accounts		409,377
Increase in allowance for inventory obsolescence		7,967
Loss on disposal of fixed assets
Change in operating assets and liabilities:
Accounts and other receivable		584,770
Inventory		(21,573)
Prepaid expenses and other current assets		261,103
Other assets		77,011
Accounts payable		(2,484,555)
Accrued liabilities		(1,839,631)
Accrued interest
Deferred revenue
Other liabilities		(48,179)
Net cash used in operating activities		(7,838,146)
CASH FLOWS FROM INVESTING ACTIVITIES:
Changes in restricted cash		(40)
Property and equipment acquisitions
Proceeds from sale of equipment		100,000
Net cash provided by (used in) investing activities		99,960
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and preferred stock, net of issuance costs
Proceeds from issuance of debtor-in-possession note payable, net of issuance costs
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents		(7,738,186)
Cash and cash equivalents, beginning of period		10,358,209
Cash and cash equivalents, end of period	$ 10,358,209	2,620,023
Supplemental cash flow information
Interest expense paid in cash		3,629
Cash flows related to reorganization items, net		1,507,863
Non-cash financing and investing activities
Issuance of common stock		217,936
Issuance of preferred stock to settle debt		8,288,719
Investor [Member]
Non-cash financing and investing activities
Issuance of common stock		226
Predecessor [Member]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	28,173,934		$ (52,808,108)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash interest expense			39,312,841
Non-cash gain on reorganization	(34,869,565)
Change in fair value of derivative liabilities			(29,846,821)
Impairment of intangible assets and goodwill			27,054,517
Stock-based compensation	55,081		782,755
Depreciation and amortization	289,360		740,973
Non cash debtor-in-possession note payable debt issuance costs	278,303
Deferred income tax provision			(89,013)
Increase in allowance for doubtful accounts			179,470
Increase in allowance for inventory obsolescence			30,240
Loss on disposal of fixed assets			6,754
Change in operating assets and liabilities:
Accounts and other receivable	(274,200)		695,612
Inventory	106,108		271,995
Prepaid expenses and other current assets	194,835		1,138,191
Other assets	(61,427)
Accounts payable	2,024,959		(810,970)
Accrued liabilities	1,159,737		(2,739,346)
Accrued interest	172,651		2,117,847
Deferred revenue	(261,075)		(280,855)
Other liabilities	(76,992)		(150,796)
Net cash used in operating activities	(3,088,291)		(14,394,714)
CASH FLOWS FROM INVESTING ACTIVITIES:
Changes in restricted cash	(14)
Property and equipment acquisitions			(698,172)
Proceeds from sale of equipment			68,778
Net cash provided by (used in) investing activities	(14)		(629,394)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and preferred stock, net of issuance costs	7,052,500
Proceeds from issuance of debtor-in-possession note payable, net of issuance costs	5,471,697
Net cash provided by financing activities	12,524,197
Net (decrease) increase in cash and cash equivalents	9,435,892		(15,024,108)
Cash and cash equivalents, beginning of period	922,317	$ 10,358,209	15,946,425
Cash and cash equivalents, end of period	10,358,209		922,317
Supplemental cash flow information
Interest expense paid in cash	79,605		563
Cash flows related to reorganization items, net	1,839,560
Non-cash financing and investing activities
Issuance of common stock
Issuance of preferred stock to settle debt
Predecessor [Member] | Investor [Member]
Non-cash financing and investing activities
Issuance of common stock

Note 1 - Description of Busines

Note 1 - Description of Business and Bankruptcy Proceedings	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Nature of Operations [Text Block]	Note 1 – Description of Business and Bankruptcy Proceedings Description of Business Nuo Therapeutics, Inc. (“ Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a biomedical company marketing its product primarily within the U.S. We commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The use of autologous (from self) biological therapies for tissue repair and regeneration is part of a transformative clinical strategy designed to improve long term recovery in complex chronic conditions with significant unmet medical needs. Growth opportunities for the Aurix System in the United States in the near to intermediate term include the treatment of chronic wounds with Aurix in: (i) the Medicare population under a National Coverage Determination (“NCD”), when registry data is collected under the Coverage with Evidence Development (“CED”) program of the Centers for Medicare & Medicaid Services (“CMS”); and (ii) the Veterans Affairs (“VA”) healthcare system and other federal accounts settings. As of December 31, 2016, the Aurix point of care technology for the safe and efficient separation of autologous blood to produce a platelet based therapy for the chronic wound care market. Prior to the Effective Date (as defined below), we had two May 5, 2016, Bankruptcy Proceedings On January 26, 2016, d a voluntary petition in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) seeking relief under Chapter 11 11 16 10192 11 On April 25, 2016 Confirmation Date”), the Bankruptcy Court entered an Order Granting Final Approval of Disclosure Statement and Confirming Debtor’s Plan of Reorganization (the “Confirmation Order”), which confirmed the Modified First Amended Plan of Reorganization of the Debtor under Chapter 11 Scenario A contemplated by the Plan of Reorganiza tion became effective on May 5, 2016 $0.0001 Upon emergence from bankruptcy on the Effective Date, the Company applied fresh start accounting, resulting in the Company becoming a new entity for financial reporting purposes (see Note 2 – Fresh Start Accounting May 5, 2016 December 31, 2016, May 4, 2016, May 5, 2016. May 5, 2016 Common Stock R ecapitalization In accordance with the Plan of Reorganization, as of the Effective Date, the Company issued 7,500,000 Recapitalization Shares”) of new common stock, par value $0.0001 $7,300,000 $7,052,500 200,000 7,500,000 $100,000 10 Debt “Series A Preferred Stock 6,180,000 May 5, 2021 , November 5, 2016 $0.50 $1.00 A significant majority of the Recapitali zation Investors executed backstop commitments to purchase up to 12,800,000 $3,000,000 June 30, 2017. With respect to each Recapitalization Investor who executed a Backstop Commitment, the commitment terminates on the earlier of: (i) the date on which the Company receives net proceeds (after deducting all costs, expenses and commi ssions) from the sale of New Common Stock in the aggregate amount of the Backstop Commitment; (ii) the date that all shares of Series A Preferred Stock (as defined below) have been redeemed by the Company; or (iii) the date that all shares of Series A Preferred Stock are no longer owned by entities affiliated with Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Private Design Fund II, L.P. (the “Deerfield Lenders” or “Deerfield”). We refer to this date as the “Termination Date.” Under the terms of the Backstop Commitment, the Company is obligated to pay to the committed Recapitalization Investors a commitment fee of $250,000 upon the Termination Date . As of the Effective Date, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Recapitalization Investors. The Registration Rights Agreement provides certain resale registration rights to the Recapitalization Investors with respect to securities received in the Recapitalization Financing. Pursuant to the Registration Rights Agreement, the Company filed a registration statement, which was declared effective on January 11, 2017, Issuance of New Common Stock to Holders of Old Common Stock As of the Effective Date, the Company committed to the issuance of up to 3,000,000 d 2,264,612 March 28, 2016, July 5, 2016, The 2,264,612 serted ownership of a number of shares of Old Common Stock that matched the Company’s records or could otherwise be confirmed at a rate of one 41.8934 March 28, 2016. Issuance of Shares in Exchange for Administrative Claims On June 20, 2016, 162,500 Administrative Claim Shares”) pursuant to the Order Granting Application of the Ad Hoc Equity Committee Pursuant to 11 503(b)(3)(D) 503(b)(4) June 20, 2016. 503(b)(3)(D) 503(b)(4) 162,500 100,000 62,500 $62,500 December 2015 Series A Preferred Stock On the Effective Date, the Company filed a Certificate of Designations of Series A Preferred Stock (the “ Certificate of Designations”) with the Delaware Secretary of State, designating 29,038 $0.0001 29,038 1145 The Series A P referred Stock has no stated maturity date, is not convertible or redeemable, and carries a liquidation preference of $29,038,000, one one five one (1%) Assignment and Assumption Agreement; Transition Services Agreement Pursuant to the Plan, on May 5, 2016, Assignee”), the designee of the Deerfield Lenders, to assign to the Assignee the Company’s rights, title and interest in and to its existing license agreement with Arthrex, and to transfer and assign to the Assignee associated intellectual property owned by the Company and licensed thereunder, as well as rights to collect royalty payments thereunder. The assignment and transfer was effected in exchange for a reduction of $15,000,000 On the Effective Date, the Company and the Assignee entered into a Transition Services Agreement in which the Company agreed to continue to service its license agreement with Arthrex for a transition period. Termination of Deerfield Facility Agreement and DIP Credit Agreement On the Effective Date, the obligations of the Company under the Deerfield Facility Agreement, and under the DIP Credit Agreement (as defined below in Note 10 Debt

Note 2 - Fresh Start Accounting

Note 2 - Fresh Start Accounting	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block]	Note 2 – Fresh Start Accounting Upon the Company ’s emergence from Chapter 11 50% May 4, 2016, January 1, 2016 May 4, 2016 Upon the application of fresh st art accounting, the Company allocated the reorganization value to its individual assets based on their estimated fair values. Reorganization value represents the fair value of the Successor Company’s assets before considering liabilities, and the excess of reorganization value over the fair value of identified tangible and intangible assets is reported separately on the consolidated balance sheet as goodwill. The Company, with the assistance of external valuation specialists, estimated the enterprise valu e of the Company upon emergence from Chapter 11 $17.9 May 5, 2016 December 31, 2025, 3.4% 2025. The Company ’s future cash flow projections included a variety of estimates and assumptions that had a significant effect on the determination of the Company’s enterprise value. While the Company considered such estimates and assumptions reasonable, they are inherently subject to significant business, economic and competitive uncertainties, many of which are beyond the Company’s control and, therefore, may 2025; 29% ● The reorganization value, estimated at approximately $24.0 May 5, 2016. ● Each liability existing as of May 5, 2016 ● Deferred tax assets and liabilities have been recognized for differences between the assigned values and the tax basis of the recognized assets and liabilities, and have been fully valued as of May 5, 2016 Pursuant to fresh start accounting, the Company allocated the d etermined reorganization value to the Successor Company’s assets as follows (in thousands): Enterprise Value $ 17,889 Plus estimated fair value of liabilities 6,161 Reorganization Value 24,050 Less: Estimated fair value of tangible assets (13,574 ) Estimated fair value of identifiable intangible assets (8,397 ) Goodwill $ 2,079 Upon the adoption of fresh start accounting, the Successor Company adopted the significant accounting policies of the Predecessor Company (see Note 3 – Liquidity and Summary of Significant Accounting Policies May 4, 2016 Predecessor Company Reorganization Adjustments Fresh Start Adjustments Successor Company ASSETS Current assets Cash and cash equivalents $ 3,305,709 $ 7,052,500 (1) $ 10,358,209 Restricted cash 53,463 53,463 Accounts and other receivable, net 1,288,445 1,288,445 Inventory, net 56,348 56,348 Prepaid expenses and other current assets 611,593 $ (16,053 )(b) 595,540 - Total current assets 5,315,558 (16,053 ) 7,052,500 12,352,005 Property and equipment, net 865,716 865,716 Deferred costs and other assets 355,741 355,741 Intangible assets, net 2,406,457 (2,406,457 )(a) 8,397,000 (2) 8,397,000 Goodwill - 2,079,284 (2) 2,079,284 TOTAL ASSETS $ 8,943,472 $ (2,422,510 ) $ 17,528,784 $ 24,049,746 LIABILITIES AND EQUITY (DEFICIT) Current liabilities not subject to compromise Accounts payable $ 2,877,170 $ 2,877,170 Accrued expenses and liabilities 3,112,244 3,112,244 Accrued interest - - Deferred revenue, current portion 899,920 $ (899,920 )(c) - Convertible debt subject to put rights - - Short term debtor-in-possession note payable 5,750,000 (5,750,000 )(d) - Total current liabilities not subject to compromise 12,639,334 (6,649,920 ) - 5,989,414 Non-current liabilities not subject to compromise Deferred revenue - - Other liabilities 171,613 171,613 Total non-current liabilities not subject to compromise 171,613 - - 171,613 Liabilities subject to compromise Accounts payable 214,554 (214,554 )(e) - Accrued expenses and liabilities 559,202 (559,202 )(e) - Accrued interest 3,316,121 (3,316,121 )(d) - Deferred revenue - - Convertible debt subject to put rights 35,000,000 (35,000,000 )(d) - Derivative liabilities - - Other liabilities - - Total liabilities subject to compromise 39,089,877 (39,089,877 ) - - TOTAL LIABILITIES 51,900,824 (45,739,797 ) - 6,161,027 Conditionally redeemable common stock 500,000 (500,000 )(f) - Common stock outstanding, at par 12,477 (12,477 )(f) 750 (1) 750 Common stock issuable 392,950 (392,950 )(f) - Preferred stock outstanding, at par - 3 (3) 3 Additional paid-in capital 126,011,808 (126,011,808 )(f) 17,887,966 (4) 17,887,966 Retained earnings (accumulated deficit) (169,874,587 ) 170,234,522 (g) (359,935 )(5) - TOTAL EQUITY (DEFICIT) (43,457,352 ) 43,817,287 17,528,784 17,888,719 TOTAL LIABILITIES AND EQUITY (DEFICIT) $ 8,943,472 $ (2,422,510 ) $ 17,528,784 $ 24,049,746 Reorganization Adjustments (a) As a result of fresh start accounting, all intangible assets existing as of the Effective Date were established at fair value. This adjustment eliminates the carrying value of previously existing intangible assets as of the Effective Date, as the underlying Angel assets were assigned to Deerfield pursuant to the Plan of Reorganization. (b) Pursuant to the Plan of Reorganization, the Company assigned to Deerfield the Company ’s: (i) rights, title and interest in and to its existing license agreement with Arthrex; (ii) the associated intellectual property owned by the Company and licensed under such agreement; and (iii) rights to collect royalty payments thereunder. As such, certain prepaid expenses related to the Angel business were eliminated. (c) Pursuant to the Plan of Reorganization, the Company assigned to Deerfield the Company ’s (i) rights, title and interest in and to its existing license agreement with Arthrex, (ii) the associated intellectual property owned by the Company and licensed under such agreement, and (iii) rights to collect royalty payments thereunder. As such, all deferred revenue related to the existing license agreement with Arthrex as of the Effective Date was eliminated. (d) Pursuant to the Plan of Reorganization, the Company ’s obligations under the Deerfield Facility Agreement, including accrued interest, were cancelled, and the Company ceased to have any obligations thereunder. Additionally, pursuant to the Plan of Reorganization, the DIP Credit Agreement was terminated. (e) Represents claims not expected to be settled in cash. (f) Pursuant to the Plan of Reorganization, all equity interests of the Company, including but not limited to all shares of the Company ’s common stock, $0.0001 (g) Represents the cumulative impact of the reorganization adjustments: Description Adjustment Amount Elimination of existing intangible assets (a) $ (2,406,457 ) Elimination of prepaid Angel expenses (b) (16,053 ) Elimination of Angel deferred revenue (c) 899,920 Termination of debt agreements and accrued interest (d) 44,066,121 Elimination of various payables and accruals (e) 773,756 Cancellation of existing equity (f) 126,917,235 $ 170,234,522 Fresh Start Adjustments (1) Pursuant to the Plan of Reorganization, as of the Effective Date, the Company issued 7,500,000 New Common Stock, par value $0.0001 $7,052,500. 6,180,000 May 5, 2021 , November 5, 2016 $0.50 $1.00 12,800,000 $3,000,000. June 30, 2017 . (2) Represents identifiable intangible assets of approximately $8.4 $2.1 ’s assets before considering liabilities, and the excess of reorganization value over the fair value of identified tangible and intangible assets is reported separately on the consolidated balance sheet as goodwill. The Company, with the assistance of external valuation specialists, estimated the enterprise value of the Company upon emergence from Chapter 11 $17.9 s cash and cash equivalents. The estimate is based on a calculation of the present value of the projected future cash flows of the Company from May 5, 2016 December 31, 2025, In applying fresh start accounting, the Company followed these principles: ● The reorganization value, estimated as approximately $24.0 May 5, 2016. ● Each liability existing as of May 5, 2016 ● Deferred tax assets and liabilities have been recognized for differences between the assigned values and the tax basis of the recognized assets and liabilities, and have been fully valued as of May 5, 2016 Pursuant to fresh start accounting the Company allocated the determined reorganization value to the Successor Company’s assets as follows (in thousands): Enterprise Value $ 17,889 Plus estimated fair value of liabilities 6,161 Reorganization Value 24,050 Less: Estimated fair value of tangible assets (13,574 ) Estimated fair value of identifiable intangible assets (8,397 ) Goodwill $ 2,079 (3) Pursuant to the Plan of Reorganization, on the Effective Date, the Company issued 29,038 $29,038,000, (4) Reflects the cumulative impact of the fresh start adjustments described above on additional paid-in-capital: Description Adjustment Amount Cash proceeds from issuance of common stock (1) $ 7,052,500 Establishment of intangible assets (2) 10,476,284 Net assets of the predecessor (5) 359,935 Less par value of common and preferred stock (3) (753 ) $ 17,887,966 (5) Reflects the elimination of retained earnings upon the application of fresh start accounting. Reorganization Items, net Costs directly attributable to the bankruptcy proceedings and implementation of the Plan are reported as reorganization items, net. A summary of reorganization items, net is presented in the following tables: Period from May 5, 2016 through December 31, 2016 Period from January 1, 2016 through May 4, 2016 Successor Predecessor Professional fees $ 324,551 $ 3,598,216 Net gain on reorganization adjustments - (34,869,566 ) Reorganization items, net $ 324,551 $ (31,271,350 ) Cash payments for reorganization items $ 1,507,863 $ 1,839,560

Note 3 - Liquidity and Summary

Note 3 - Liquidity and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3 – Liquidity and Summary of Significant Accounting Principles Liquidity Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, lack of operating history, and uncertainty of future profitability and pos sible fluctuations in financial results. Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, and executing licensing arrangements, and to a lesser extent by generating royalties and product revenues. We have incurred, and continue to incur, recurring losses and negative cash flows. On the Effective Date, the obligations of the Company under the Deerfield Facility Agreement and the DIP Credit Agreement were cancelled and the Company ceased to have any obligations thereunder. At December 31, 2016, $2.6 The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. After our emergence from bankruptcy on May 5, 2015, combined with the $3.0 June 30, 2017, March 2018. However, if we are unable to increase our revenues significantly or control our costs as effectively as expected, then we may second third 2017, December 31, 2017, additional capital beyond the Backstop Commitment More specifically, if we are unable to increase revenues or control costs in this manner, we may may We believe, based on the operating cash requirements and capital expenditures expected for 2017, cash on hand at December 31, 2016, $3.0 11 Equity and Stock-Based Compensation ), which is available June 30, 2017 , is adequate to fund operations for at least twelve As noted in Note 2 – Fresh Start Accounting Basis of Presentation The accompanying consolidated financial statements have been p repared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Upon emergence from bankruptcy on the Effective Date, the Company applied fresh start accounting, resulting in the Company becoming a new entity for financial reporting purposes (see Note 2 Fresh Start Accounting May 5, 2016 Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned and controlled subsidiary Aldagen, Inc. (“ Aldagen”). All significant inter-company accounts and transactions are eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and l iabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the application of fresh start accounting, stock-based compensation, allowance for inventory obsolescence, allowance for doubtful accounts, valuation of derivative liabilities, contingent liabilities, fair value and depreciable lives of long-lived assets (including property and equipment, intangible assets and goodwill), deferred taxes and associated valuation allowance and the classification of our long-term debt. Actual results could differ from those estimates. Credit Concentration We generate accounts receivable from th e sale of our products. Specific customer receivables balances in excess of 10% December 31, 2016 December 31, 2015 Successor Predecessor December 31, 2016 December 31, 2015 Customer A 58 % 47 % Customer B 10 % 21 % Revenue from significant customers exceeding 10% Period from May 5, 2016 through December 31, 2016 Period from January 1, 2016 through May 4, 2016 Year ended December 31, 2015 Successor Predecessor Predecessor Customer B $ - $ 78% $ 67% Customer C - - 26% Customer D 22% - - Customer E 16% - - Historically, we used single suppliers for several components of the Aurix™ product line. We outsource the manufacturing of various products to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is no assurance that one Cash Equivalents We consider all highly liquid instruments purchased with an original maturity of three to be cash equivalents. Cash and cash equivalents potentially subject us to a concentration of credit risk, as approximately $2.4 $250,000 December 31, 2016. Accounts Receivables We generate accounts receivables from the sale of our products. We provide for an allowanc e against receivables for estimated losses that may December 31, 2016 2015, $409,000 $97,000, December 31, 2016. Inventory Our inventory is produced by third first first ut basis and is stated at the lower of cost or net realizable value. We maintain an inventory of kits, reagents, and other disposables that have shelf-lives that generally range from 18 two As of December 31, 2016, of $18,123 $59,798 December 31, 2015, $115,792 $196,500 We provide for an allowance against inventory for estimated losses that may ’s remaining shelf-life and our anticipated ability to sell such inventory, which is estimated using historical usage and future forecasts, within its remaining shelf life. At December 31, 2016 2015, $8,000 $58,000, P roperty and Equipment Property and equipment is stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over its estimated useful life ranging from one four four six three six Ce ntrifuges may Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may rability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. Goodwill and Other Intangible Assets Predecessor intangible assets and goodwill In the Predecessor Company financial statements, intangible assets were acquired as part of our acquisition of the Angel business and Aldagen, and consisted of definite-lived and indefinite-lived intangibl e assets, including goodwill. During the quarter ended September 30, 2015, $22.6 September 30, 2015, $1.1 zero. December 31, 2015, In conjunction with the application of fresh start accounting, all remaining definite lived intangible assets were written off as of the Effective Date (See Note 2 – Fresh Start Accounting Successor intangible assets and goodwill In the Successor Company financial statements, intangible assets were established as part of fresh start accounting and relate to trademarks, technology, clinician relationships, and goodwill (see Note 2 – Fresh Start Accounting Our definite-lived intangible assets include trademarks, technology (including patents), and clinician relationships, and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstance s indicate that the carrying amount of the asset may Goodwill represents the excess of reorganization value over the fair value of tangible and identifiable intangib le assets and the fair value of liabilities as of the Effective Date. Goodwill is not amortized, but is subject to periodic review for impairment. Goodwill is reviewed annually, as of October 1, one Before employing detailed impairment testing methodologies, we first ive factors relevant to our reporting unit. When performing the qualitative assessment, we evaluate events and circumstances that would affect the significant inputs used to determine the fair value of the goodwill. Events and circumstances evaluated include: macroeconomic conditions that could affect us, industry and market considerations for the medical device industry that could affect us, cost factors that could affect our performance, our financial performance (including share price), and consideration of any company specific events that could negatively affect us, our business, or the fair value of our business. If we determine that it is more likely than not that goodwill is impaired, we will then apply detailed testing methodologies. Otherwise, we will conclude that no impairment has occurred. Detailed impairment testing involves comparing the fair value of our one l impairment has occurred. If the carrying value of the reporting unit exceeds its fair value, a second second one one one Successor Company intangible assets and goodwill were not impaired as of December 31, 2016. Co nditionally Redeemable Common Stock The Maryland Venture Fund (“ MVF,” part of Maryland Department of Business and Economic Development) had an investment in the Predecessor Company’s common stock, and could have required us to repurchase the common stock, at MVF’s option, upon certain events outside of our control. MVF’s common stock was classified as “contingently redeemable common shares” in the Predecessor Company’s accompanying consolidated balance sheets. The contingently redeemable common shares were cancelled as of the Effective Date. Revenue Recognition – Successor Company We recognize revenue when the four (1) (2) been rendered; (3) (4) We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recogni zed upon shipment of products to the customers. We do not maintain a reserve for returned products, as in the past those returns have not been material and are not expected to be material in the future. Percentage-based fees on licensee sales of covered products are generally recorded as products are sold by licensees, and are reflected as royalties in the consolidated statements of operations. Direct costs associated with product sales and royalty revenues are recorded at the time that revenue is recognized. Revenue Recognition – Predecessor Company The Predecessor Company provided for the sale of our products, including disposable processing sets and supplies to customers, and to Arthrex as distributor of the Angel product line. Revenue from the sale of pr oducts was recognized upon shipment. Usage or leasing of blood separation equipment As a result of the acquisition of the Angel business, we acquired various multiple element revenue arrangements that combined the (i) usage or leasing of blood separation processing equipment, (ii) maintenance of processing equipment, and (iii) purchase of disposable processing sets and supplies. We assigned these multiple element revenue arrangements to Arthrex in 2013 Deferred revenue at December 31, 2015 ted of prepaid licensing revenue of approximately $1.0 $0.1 $0.14 January 1, 2016 May 4, 2016. $0.4 December 31, 2015. License Agreement with Rohto The Company ’s license agreement with Rohto (See Note 4 – Distribution, Licens ing and Collaboration Arrangements $3.0 three March 31, 2015. Segments and Geographic Information Approximately 11% 22% January 1, 2016 May 4, 2016 May 5, 2016 December 31, 2016, ximately 31% December 31, 2015. one Exit Activities and Realignment In May 2014, COVER-Stroke Phase 2 401. 401 $0.2 December 31, 2016 2015. On August 11, 2015, the Board of Directors approved our realignment plan with the goal of preserving and maximizing, for the benefit of our stockholders, the value of our existing assets. The plan eliminated approximately 30% December 4, 2015, 22% seven January 2016, four $0.9 December 31, 2015. $0.5 four January 2016 January 1, 2016 May 4, 2016. $0.5 four January January 1, 2016 May 4, 2016, $0.2 $0.2 $0.4 December 31, 2015. December 31, 2016 $0.3 December 31, 2015). Stock-Based Compensation Prior to the Effective Date, the Company, from time to time, issued stock options or stock awards to employees, directors, consultants, and other service providers under its 2002 LTIP”) or 2013 11 – Equity and Stock-Based Compensation All outstanding stock options were cancelled as of the Effective Date. In July 2016, August 2016 2016 “2016 November 21, 2016, 2016 2016, 1,370 ,000 The fair value of employee stock options is measured at the date of grant. Expected volatilities for the 2016 five zero. 2016 2015 Risk free rate 1.8 - 2.0% 1.4 - 1.7% Weighted average expected years until exercise 4.8 - 6.0 6.3 Expected stock volatility 83% 93 - 117% Dividend yield - - Stock-based compensation for awards granted to non-employees is periodically re-measured as the underlying awards vest. The Company recognizes an expense for such awards throughout the performance period as the services are provided by the non-employees, based on the fair value of these options and warrants at each reporting period. The fair value of stock options and compensatory warrants issued to service providers utilizes the same methodology with the exception of the expected term. For awards to non-employees, the Company estimates that the options or warrants will be held for the full term. Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. All of our tax years remain subject to examination by the tax authorities. For the year ended December 31, 2015, elates exclusively to a deferred tax liability associated with the amortization for tax purposes of the Predecessor Company’s goodwill. The deferred tax liability was eliminated in the third 2015 The Company ’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no such items in 2016 2015. Basic and Diluted Earnings (Loss) per Share Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding (includ ing contingently issuable shares when the contingencies have been resolved) during the period. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is a nti-dilutive. For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding (including contingently issuable shares when the contingencies have been resolved) plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible debt using the if-converted method. All of the Company ’s outstanding stock options and warrants were considered anti-dilutive for the periods from January 1, 2016 May 4, 2016, May 5, 2016 December 31, 2016, December 31, 2015. January 1, 2016 May 4, 2016. Period from May 5, 2016 Period from January 1, 2016 Year ended December 31, 2015 Successor Predecessor Predecessor Shares underlying: Common stock options 1,265,000 9,173,119 11,069,166 Stock purchase warrants 6,180,000 113,629,178 116,034,682 Convertible debt - - 73,342,730 Earnings (loss) per share are calculated for basic and diluted earnings per share as follows: Period from May 5, 2016 Period from January 1, 2016 Year ended December 31, 2015 Successor Predecessor Predecessor Numerator for basic income (loss) per share $ (5,695,027 ) $ 28,173,934 $ (52,808,108 ) Numerator adjustment for potential dilutive securities - 172,546 - Numerator for diluted income (loss) per share (5,695,027 ) 28,346,480 (52,808,108 ) Denominator for basic income (loss) per share weighted average outstanding common shares 9,895,966 125,951,100 125,951,100 Dilutive effect of convertible debt - 67,307,692 - Denominator for diluted income (loss) per share weighted average outstanding common shares 9,895,966 193,258,792 125,951,100 Basic and diluted earnings (loss) per share Basic $ (0.58 ) $ 0.22 $ (0.42 ) Diluted $ (0.58 ) $ 0.15 $ (0.42 ) Recently Adopted Accounting Pronouncements In April 2015, FASB”) issued guidance as to whether a cloud computing arrangement (e.g., software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements) includes a software license and, based on that determination, how to account for such arrangements. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The amendment is effective for reporting periods beginning after December 15, 2015, may January 1, 2016; In April 2015, a direct deduction from the carrying amount of that debt liability, in the same manner as debt discounts, rather than as an asset. The standard is effective for reporting periods beginning after December 15, 2015, January 1, 2016; In September 2015, lting from business combinations. Under the guidance, an acquirer will be required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined. The guidance requires an entity to present separately on the face of the income statement, or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date. The standard is effective for reporting periods beginning after December 15, 2015. January 1, 2016; In August 2014, ’s ability to continue as a going concern. Under U.S. GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Previously, there was no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. This was issued to provide guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this update are effective for the annual period ending after December 15, 2016, December 31, 2016; Unadopted Accounting Pronouncements In May 2014, ASB issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five 1) 2) 3) 4) 5) August 2015, one December 15, 2017, December 15, 2016. March 2016, April 2016, May 2016, two March 3, 2016 May 2016, In Jul y 2015, 330 December 15, 2016, In November 2015, to current and noncurrent amounts. Under this guidance, deferred tax liabilities and assets will be classified as noncurrent amounts. The standard is effective for reporting periods beginning after December 15, 2016. In February 2016, long-term leases on the balance sheet, and expands disclosure requirements regarding leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018, In March 2016, or, and financial statement disclosure of, stock-based compensation awards. Under the guidance, all excess tax benefits and tax deficiencies related to stock-based compensation awards are to be recognized as income tax expenses or benefits in the income statement, and excess tax benefits should be classified along with other income tax cash flows in the operating activities section of the statement of cash flows. Under the guidance, companies can also elect to either estimate the number of awards that are expected to vest, or account for forfeitures as they occur. In addition, the guidance amends some of the other stock-based compensation awards guidance to more clearly articulate the requirements and cash flow presentation for withholding shares for tax-withholding purposes. The guidance is effective for reporting periods beginning after December 15, 2016, In March 2016, debt hosts. The amendments of this guidance are effective for reporting periods beginning after December 15, 2016, In June 2016, financial instruments, including trade receivables. The guidance eliminates the probable initial recognition threshold that was previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity's current estimate of all future expected credit losses. Under the previous guidance, an entity only considered past events and current conditions. The guidance is effective for fiscal years beginning after December 15, 2019. December 15, 2018. In August 2016, the FASB issued guidance on the classification of certain cash receipts and cash payments in the statement of cash flows, including those related to debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance, and distributions received from equity method investees. The guidance is effective for fiscal years beginning after December 15, 2017. may In November 2016, e requires that amounts generally described as restricted cash and restricted cash equivalents be included in cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the statement of cash flows. The guidance is effective for the fiscal years beginning after December 15, 2017. In January 2017, 2 fair value of goodwill under Step 2, zero 2 December 15, 2021. January 1, 2017. In January 2017, December 15, 2018. We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our results of operations, financial position, or cash flows.

Note 4 - Distribution, Licensin

Note 4 - Distribution, Licensing and Collaboration Arrangements	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Distributors and License Agreement [Text Block]	Note 4 – Distribution, Licensing and Collaboration Arrangements Distribution and License Agreement with Arthrex In 2013, e entered into a Distributor and License Agreement (the “Original Arthrex Agreement”) with Arthrex. The term of the Original Arthrex Agreement was originally for five three one five $5.0 October 16, 2015, March 31, 2016, April 2016, Pursuant to the Plan, on May 5, 2016, Assignee”), the designee of the Deerfield Lenders, to assign to the Assignee the Company’s rights, title and interest in and to the Arthrex Agreement, and to transfer and assign to the Assignee associated intellectual property owned by the Company and licensed thereunder, as well as rights to collect royalty payments thereunder. The assignment and transfer was effected in exchange for a reduction of $15,000,000 On the Effective Date, the Company and the Assignee entered into a Transition Services Agreement, in which the Company agreed to continue to service the Arthrex Agreement for a transition period. Transition services fees of $0.05 May 5, 2016 December 31, 2016 On October 20, 2016, greement (the “Three Party Letter Agreement”) with Arthrex and Deerfield SS, LLC (the “Assignee”), which extended the transition period under the Transition Services Agreement through January 15, 2017. $201,200 October 28, 2016, October 27, 2016: three $33,333 $33,333 three December 31, 2016 January 15, 2017. June 30, 2016, Distribution and License Agreement with Rohto In September 2009, with Millennia Holdings, Inc. (“Millennia”) for the Company’s Aurix System in Japan. In January 2015, Rohto”) a royalty bearing, nontransferable, exclusive license, with limited right to sublicense, to use certain of the Company’s intellectual property for the development, import, use, manufacturing, marketing, sale and distribution for all wound care and topical dermatology applications of the Aurix System and related intellectual property and know-how in human and veterinary medicine in Japan in exchange for an upfront payment from Rohto of $3.0 one $1.5 $3.0 may Collaboration Agreement with Restorix Health On March 22, 2016, Agreement (the “Collaboration Agreement”) with Restorix Health (“Restorix”), pursuant to which we agreed to provide Restorix with certain limited geographic exclusivity benefits over a defined period of time for the usage of the Aurix System in up to 30 125 three two one Pursuant to the Collaboration Agreement, the Company agreed to provide: (i) clinical support services by its clinical staff as reasonably agreed between the Company and Restorix as necessary and appropriate, (ii) reasonable and necessary support regarding certain reimbursement activities, (iii) coverage of Institutional Review Board (“IRB”) fees and payment to Restorix for certain training costs subject to certain limitations and (iv) community-focused public relations materials for participating RXH Partner Hospitals to promote the use of Aurix and participation in the Protocols. Pursuant to the Collaboration Agreement, Restorix agreed to: (i) provide access and support as reasonably necessary and appropriate at up to 30 Subject to the satisfaction of certain conditions, during the term of the Collaboration Agreement: (i) Restorix will have site specific geographic exclusivity for usage of Aurix in connectio n with treatment of patients in the Protocols within a 30 19 Under the Collaboration Agreement, the Company will pay Restorix or the RXH Partner Hospital, as the case may and delivery of a patient data set. In addition, the Company is responsible to pay for any IRB fees necessary to conduct the Protocols and enroll patients, and to pay Restorix a training cost stipend per site. Each RXH Partner Hospital will pay the Company the then-current product price ($700 2016, $750 Boyalife Distribution Agreement Effective as of May 5, 2016, . (“Boyalife”), an entity affiliated with the Company’s significant shareholder, Boyalife Investment Fund I, Inc., entered into an Exclusive License and Distribution Agreement (the “Boyalife Distribution Agreement”) with an initial term of five May 5, 2016 $500,000 90 December 31, 2018, $40, third first $250,000 .

Note 5 - Receivables

Note 5 - Receivables	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 5 – Receivables Accounts and other receivable, net consisted of the following: Successor Predecessor December 31, December 31, 2016 2015 Trade receivables $ 100,660 $ 460,763 Other receivables 603,015 650,230 703,675 1,110,993 Less allowance for doubtful accounts (409,377 ) (96,748 ) $ 294,298 $ 1,014,245 Other receivables at December 31, 2016 2015 the cost of raw materials required to manufacture the Angel products that were purchased by the Company and immediately resold, at cost, to the contract manufacturer. We assigned all of our rights under the Arthrex Agreement to Deerfield on the Effective Date. The allowance for doubtful accounts at December 31, 2016

Note 6 - Property and Equipment

Note 6 - Property and Equipment	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 6 — Property and Equipment Property and equipment, net consisted of the following: Successor Predecessor December 31, December 31, 2016 2015 Medical equipment $ 405,096 $ 1,195,467 Office equipment 48,888 142,827 Software 257,619 523,571 Manufacturing equipment 34,899 307,851 Leasehold improvements 19,215 32,130 765,717 2,201,846 Less accumulated depreciation and amortization (279,601 ) (1,086,632 ) $ 486,116 $ 1,115,214 For the period from January 1, 2016 May 4, 2016 $249,000, $80,000 $9,000 $37,000 $67,000 $56,000 May 5, 2016 December 31, 2016 $280,000, $100,000 $12,000 $70,000 $98,000 For the year ended December 31, 2015 $433,000, $246,000 $25,000 $68,000 $94,000

Note 7 - Goodwill and Other Int

Note 7 - Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	Note 7 – Goodwill and Other Intangible Assets Our definite-lived intangible assets as of December 31, 2016 2015 Successor Predecessor December 31, December 31, 2016 2015 Trademarks $ 917,000 $ 1,047,000 Technology 6,576,000 2,355,000 Customer and clinician relationships 904,000 708,000 8,397,000 4,110,000 Accumulated amortization trademarks (39,934 ) (184,981 ) Accumulated amortization technology (477,290 ) (902,750 ) Accumulated amortization customer and clinician relationships (39,368 ) (508,875 ) (556,592 ) (1,596,606 ) $ 7,840,408 $ 2,513,394 Goodwill Predecessor Company Goodwill represents the purchase price of acquisitions in excess of the fair value of amounts assigned to acquired tangible or intangible assets and assumed liabilities. As a result of our acquisition of Aldagen in February 2012, $0.4 $0.7 April 2010. September 30, 2015 $1.1 zero September 30, 2015. Successor Company (see Note 2 – Fresh Start Accounting) Goodwill represents the excess of reorganization value over the fair value o f tangible and identifiable intangible assets and the fair value of liabilities as of the Effective Date. Changes in goodwill for the periods presented follows: Successor Predecessor Balance, at December 31, 2014 $ - $ 1,128,517 2015 impairment - (1,128,517 ) Balance, at December 31, 2015 - $ - Fresh start accounting 2,079,284 Balance, at December 31, 2016 $ 2,079,284 Definite-lived intangible assets – trademarks, customer and clinician relationships and technology The Predecessor Company ’s definite-lived intangible assets include Angel-related trademarks, technology (including patents) and customer relationships, and were being amortized over their useful lives ranging from eight twenty $0.1 January 1, 2016 May 4, 2016. May 4, 2016 $0.2 December 31, 2015. The Successor Company ’s Aurix related definite-lived intangible assets include trademarks, technology (including patents), and clinician relationships, and are being amortized over their useful lives ranging from nine fifteen $0.6 May 5, 2016 December 31, 2016. 2017 $ 852,000 2018 852,000 2019 852,000 2020 852,000 2021 852,000 Thereafter 3,580,000

Note 8 - Accrued Liabilities

Note 8 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 8 — Accrued Liabilities Accrued liabilities consisted of the following: Successor Predecessor December 31, December 31, 2016 2015 Customer deposits $ 72,192 $ 611,341 Accrued compensation and benefits 91,325 532,435 Other payables 124,484 518,734 Due to Arthrex - 31,785 Accrued professional fees 213,116 190,787 Accrued loss on abandonment of lease, current portion 88,560 103,173 Accrued Angel machine rework costs 465,000 465,000 $ 1,054,677 $ 2,453,255 An accrual of $600,000 2014 December 31, 2016 2015, the remaining accrued liability was $465,000 .

Note 9 - Deferred Revenue

Note 9 - Deferred Revenue	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Deferred Revenue Disclosure [Text Block]	Note 9 — Deferred Revenue Deferred revenue consists primarily of prepaid licensing revenue from the Arthrex Agreement. Revenue related to prepaid licensing is recognized on a straight-line basis over five ears, the term of the original Arthrex agreement. Revenue of approximately $402,000 December 31, 2015. $140,000 January 1, 2016 May 4, 2016 . The remaining balance of deferred revenue of approximately $900,000 January 1, 2016 May 4, 2016. 4 Distribution, Licensing and Collaboration Arrangements

Note 10 - Debt

Note 10 - Debt	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 10 – Debt Successor Company Debt As of December 31, 2016, no . Predecessor Company Debt Deerfield Facility In 2014, $35 five March 31, 2019. eld had the right to convert the principal amount of the related notes (the “Notes”) into shares of our common stock (“Conversion Shares”) at a per share price equal to $0.52. 33.33% second, third, fourth 35% first $10 first Under the terms of the facility, we also issued stock purchase warrants to purchase up to 97,614,999 $0.52 ts). We also entered into a registration rights agreement pursuant to which we filed a registration statement to register the resale of the Conversion Shares and the shares underlying the stock purchase warrants. As a result of certain non-standard anti-dilution provisions and cash settlement features, we classify the detachable stock purchase warrants and the conversion option embedded in the Notes as derivative liabilities. The derivative liabilities were recorded initially at their estimated fair value and as a result, we recognized a total debt discount on the convertible notes of $34.8 de minimis March 31, 2016 December 31, 2015. 2,709,677 2014, $1.1 December 31, 2015, Under the Deerfield Facility Agreement, we were required to maintain a compensating cash balance of $5,000,000 trol agreements in favor of the lenders, and we were required to pay to Deerfield accrued interest of approximately $2.6 October 1, 2015. December 4 18, 2015, December 18, 2015 December 18, 2015 January 7, 2016, $5,000,000 $500,000; October 1, 2015, January 7, 2016. December 28, 2015; As of January 26, 2016 he entire amount owed to them, including accrued interest. As a result of the default and our assessment that we would not be able to cure the causes of the default, as of December 31, 2015, December 31, 2015, $38.3 $5.75 29,038 January 26, 2016. Debtor-in-Possession Financing On January 28, 2016, approving the Company's debtor-in-possession financing (“DIP Financing”) pursuant to terms set forth in a senior secured, super-priority debtor-in-possession credit agreement (the “DIP Credit Agreement”), dated as of January 28, 2016, 100% On March 9, 2016, ankruptcy Court approved on a final basis the Company's motion for approval of the DIP Credit Agreement and use of cash collateral, and approved a Waiver and First Amendment to the DIP Credit Agreement (the “Waiver and First Amendment”) with the Deerfield Lenders and DIP Agent, pursuant to which the DIP Credit Agreement was approved to include certain amendments, including to set forth the material terms of the proposed restructuring of the prepetition and post-petition secured debt, unsecured debt, and equity interests of the Company, the terms of which were eventually effected pursuant to the Plan of Reorganization (as defined below). The Waiver and First Amendment provided for senior secured loans in the aggregate principal amount of up to $6,000,000 We received $5.75 January 1, 2016 May 4, 2016, $0.3 h the Plan of Reorganization, as of the Effective Date, the DIP Credit Agreement was terminated.

Note 11 - Equity and Stock-base

Note 11 - Equity and Stock-based Compensation	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 11 – Equity and Stock-Based Compensation Successor Company Common Stock Under the Second Amended and Restated Certificate of Incorporation of the Succ essor Company, it has the authority to issue a total of 32,500,000 31,500,000 $0.0001 1,000,000 $0.0001 In accordance with the Plan, as of the Effective Date, the Company issued 7,500,000 ock to the Recapitalization Investors for gross cash proceeds of $7,300,000 $7,052,500, $100,000 A significant majority of the Recapitalization Investors executed backstop commitments to purchase up to 12,800,000 of New Common Stock for an aggregate purchase price of up to $3,000,000. June 30, 2017 . With respect to each Recapitalization Investor who executed a Backstop Commitment, the commitment terminates on the earlier of (i) the date on which the Company receives net proceeds (after deducting all costs, expenses and commissions) from the sale of New Common Stock in the aggregate amount of the Backstop Commitment, (ii) the date that all shares of Series A Preferred Stock (as defined below) have been redeemed by the Company, or (iii) the date that all shares of Series A Preferred Stock are no longer owned by entities affiliated with Deerfield (“Termination Date”). Under the terms of the Backstop Commitment, the Company is obligated to pay to the committed Recapitalization Investors a commitment fee of $250,000 upon the Termination Date . Under the Plan of Reorganization, the Company committed to the issuance of up to 3,000,000 Common Stock, and subsequently issued 2,264,612 March 28, 2016, July 5, 2016, The 2,264,612 issued as of the Effective Date to Releasing Holders who asserted ownership of a number of shares of Old Common Stock that matched the Company’s records or could otherwise be confirmed, at a rate of one 41.8934 March 28, 2016. On June 20, 2016, 162,500 Administrative Claim Shares”) pursuant to the Order Granting Application of the Ad Hoc Equity Committee Pursuant to 11 503(b)(3)(D) 503(b)(4) June 20, 2016. 503(b)(3)(D) 503(b)(4) 162,500 100,000 62,500 $62,500 December 2015 Successor Company Stock Purchase Warrants As part of the Recapitalization Financing, the Company also issued Warrants to purchase 6,180,000 May 5, 2021 , November 5, 2016, $0.50 $1.00 Successor Company Series A Preferred Stock On the Effecti ve Date, the Company filed a Certificate of Designations of Series A Preferred Stock with the Delaware Secretary of State, designating 29,038 $0.0001 29,038 1145 The Series A Preferred Stock has no stated maturity date, is not convertible or redeemable, and carries a liq uidation preference of $29,038,000, one five one (1%) may $3.0 five, two thirds Predecessor Company Commo n Stock The Predecessor Company ’s Certificate of Incorporation authorized 440,000,000 425,000,000 15,000,000 one may No 2016 2015. 2014 In March 2014, $2.0 3,846,154 $0.52 five ts to purchase 2,884,615 $0.52 $1.1 de minimis December 31, 2015. $136,000 Predecessor Stock Purchase Warrants The Company had the following stock purchase warrants outs tanding at May 4, 2016 : Outstanding Exercise Price Expiration Date Classification 20,000 $0.40 June 2016 Equity 136,364 $0.66 February 2018 Equity 6,363,638 $0.75 February 2018 Equity 5,047,461 $0.65 December 2017 Equity 232,964 $0.65 December 2017 Equity 2,884,615 $0.52 March 2019 Liability 1,474,615 $0.52 March 2019 Liability 3,525,000 $0.52 June 2019 Liability 1,079,137 $0.70 February 2020 Equity 250,000 $0.70 February 2020 Equity 25,115,384 $0.52 March 2021 Liability 67,500,000 $0.52 June 2021 Liability 113,629,178 All of such warrants were cancelled in their entirety as of the Effective Date. Stock-Based Compensation Predecessor Company The Company ’s 2002 2013 10,500,000 18,000,000 June 9, 2014). As of May 4, 2016, by the Board of Directors for each option grant, and options generally vested immediately upon grant or over a period of time ranging up to four ten no January 1, 2016 May 4, 2016. May 4, 2016, $0.3 2.4 May 4, 2016, 2016, Stock Options – Incentive Plans Shares Weighted- Average Weighted- Average Aggregate Intrinsic Outstanding at January 1, 2016 11,069,166 $ 0.78 6.1 $ - Granted - $ - $ - Exercised - $ - $ - Forfeited or expired (11,069,166 ) $ 0.78 $ - Outstanding at May 4, 2016 - $ - - $ - Exercisable at May 4, 2016 - $ - - $ - Vested and expected to vest at May 4, 2016 - $ - - $ - There were no stock options granted under the Incentive Plans during 2016. 1,033,259 2015, fair value of stock options granted under the Incentive Plans during 2015 $0.18. 2015 $187,000. No 2015. December 31, 2015, $810,000 2.6 May 4, 2016, Additionally, the Company has issued certain st ock purchase warrants in exchange for the performance of services not covered by the Incentive Plans. A summary of service provider warrant activity as of the Effective Date, and changes during 2016, Warrants to Service Providers Shares Weighted- Average Weighted- Average Aggregate Intrinsic Outstanding at January 1, 2016 406,364 $ .67 3.3 $ - Granted - $ - $ - Exercised - $ - $ - Forfeited or expired (406,364 ) $ .67 $ - Outstanding at May 4, 2016 - $ - $ - Exercisable at May 4, 2016 - $ - $ - There were no 2016, no 2016. December 31, 2015, no All stock purchase warrants granted were cancelled in their entirety as of the Effective Date. Successor Company In July 2016, on August 4, 2016, 2016 “2016 first January 1, 2017) six (6%) may 1,000,000 November 21, 2016, 2016 1,500,000 2016 December 31, 2016. 2016 December 31, 2016, 2016, Stock Options – 2016 Omnibus Plan Shares Exercise Weighted- Average Aggregate Intrinsic Outstanding at May 5, 2016 - $ - - $ - Granted 1,370,000 $ 1.00 10.00 $ - Exercised - Forfeited or expired (105,000 ) $ - Outstanding at December 31, 2016 1,265,000 $ 1.00 9.51 $ - Exercisable at December 31, 2016 331,665 $ 1.00 9.51 $ - Vested and expected to vest at December 31, 2016 1,265,000 $ 1.00 9.51 $ - There were 1,370,000 2016 2016. 2016 $233,000 $56,000, No 2016. December 31, 2016, $140,000 1.4 December 31, 2016: Options Outstanding Options Exercisable Weighted Number of Average Exercise Outstanding Remaining Exercise Number Exercise Price Shares Contract Life Price Exercisable Price $1.00 1,265,000 9.51 $ 1.00 331,665 1.00 The Company has not warrants in exchange for the performance of services not covered by the 2016 2016. The Company recorded stock-based compensation expense in the periods presented as follows: Period from May 5, 2016 Period from January 1, 2016 Year Ended December 31, 2015 Successor Predecessor Predecessor Sales and marketing $ 8,963 $ 18,504 $ 156,297 Research and development 9,769 6,858 74,989 General and administrative 56,267 29,719 551,469 $ 74,999 $ 55,081 $ 782,755

Note 12 - Income Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 12 — Income Taxes Income tax (expense) benefit for the period from January 1, 2016 May 4, 2016, May 5, 2016 December 31, 2016, December 31, 2015, Period from May 5, 2016 through December 31, 2016 Period from January 1, 2016 through May 4, 2016 Year Ended December 31, 2015 Successor Predecessor Predecessor Current: Federal $ - $ - $ - State - - - Deferred: Federal 1,989,763 (9,836,756 ) 29,084,623 State 236,490 (2,237,382 ) 3,614,773 Change in valuation allowance (2,226,253 ) 12,074,138 (32,610,383 ) Total Benefit for Income Taxes $ - $ - $ 89,013 Significant components of the Company's deferred tax assets and liabilities consisted of the following at December 31, 2016 2015: December 31, 2016 December 31, 2015 Successor Predecessor Deferred tax assets: Stock-based compensation $ 29,379 $ 6,238,000 Tax credits 3,484,799 3,339,000 Deferred revenue - 462,000 Start-up and organizational costs 270,652 275,000 Tax deductible Goodwill 354,831 404,000 Property and equipment 163,755 207,000 Other 224,910 283,000 Total deferred tax assets 4,528,326 11,208,000 Deferred tax liabilities: Intangible Assets (2,374,950 ) (114,000 ) Total deferred tax liabilities (2,374,950 ) (114,000 ) Net deferred tax assets, excluding net operating loss carryforwards 2,153,376 11,094,000 Net operating loss carryforwards 50,713,527 61,076,000 52,866,903 72,170,000 Less valuation allowance (52,866,903 ) (72,170,000 ) Total deferred tax assets (liabilities) $ - $ - The following table presents a reconciliation between the U.S. federal statutory income tax rate and the Company's effective tax rate: Period from May 5, 2016 through December 31, 2016 Period from January 1, 2016 through May 4, 2016 Year Ended December 31, 2015 Successor Predecessor Predecessor U.S. federal statutory income tax 35.0 35.0 % 35.0 % State and local income tax, net of benefits 4.2 4.2 % 4.8 % Fair value of derivatives - - 22.4 % Other (0.1 )% 3.7 % (0.4 )% Valuation allowance for deferred income tax assets (39.1 )% (42.9 )% (61.6 )% Effective income tax rate - % - % 0.2 % The Company had loss carry-forwards of approximately $163.2 December 31, 2016, may 2020. may The Company does not

Note 13 - Fair Value Measuremen

Note 13 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 13 – Fair Value Measurements Financial Instruments Carried at Cost Short-term financial instruments in our consolidated balance sheets, including cash and cash equivalents other than money market funds (which are carried at fair value), accounts, and other receivables and accounts payable, are carried at cost which approximates fair value, due to their short-term nature. The fair value of our long-term convertible debt was approximately $25.4 December 31, 2015; In February 2014, CD”) from a commercial bank in the amount of $53,000. 0.10% October 24, 2016, eight June 24, 2017. 14 – Commitments and Contingencies . Fair Value Measurements Our consolidated balance sheets include certain financial instruments that are carried at fair value. Fair valu e is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: ● Level 1, ● Level 2, 1 ● Level 3, An asset ’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently, and therefore have little or no price transparency are classified as Level 3. Success or Company Financial Assets and Liabilities Measured at Fair Value The Successor Company had no financial assets and liabilities measured at fair value on a recurring or non-recurring basis as of December 31, 2016. Successor Company Non-Financial As sets and Liabilities Measured at Fair Value The Successor Company ’s property and equipment and intangible assets are measured at fair value on a non-recurring basis, upon establishment pursuant to fresh start accounting, and upon impairment. The Successor Company determined the fair value of its intangibles assets as of the Effective Date as follows: Identifiable Intangible Asset Valuation Method Significant Unobservable Inputs Estimated Fair Value Trademarks Income approach - royalty savings method Projected sales $ 917,000 Estimated royalty rates Discount rate Technology Income approach - royalty savings method Projected sales $ 6,576,000 Estimated royalty rates Discount rate Clinician Relationships Income approach - excess earnings method Projected sales $ 904,000 Estimated attrition Projected margins Discount rate No Predecessor Company Financial Assets and Liabilities Measured at Fair Value The Predecessor Company segregated its financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. The inputs used in measuring the fair value of cash and short-term investments are considered to be Level 1 three We account for our derivative financial instruments, consisting solely of certain stock purchase warrants that contain non-standard anti-dilutions provisions and/or cash settlement features, and certain conversion options embedded in our convertible i nstruments, at fair value using Level 3 ● When determining the fair value of our financial assets and liabilities using the Black-Scholes option pricing model, we are required to use various estimates and unobservable inputs, including, among other things, contractual terms of the instruments, expected volatility of our stock price, expected dividends, and the risk-free interest rate. Changes in any of the assumptions related to the unobservable inputs identified above may ● When determining the fair value of our financial assets and liabilities using binomial lattice models or other accepted valuation practices, we also are required to use various estimates and unobservable inputs, including, in addition to those listed above, the probability of certain events. As a result of our d eteriorating financial condition (as further evidenced by our filing for bankruptcy protection in January 2016) 2015, de minimis May 4, 2016 December 31, 2015. The following table represents the fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2015. As of December 31, 2015 Level 1 Level 2 Level 3 Total Assets - money market funds $ 614,283 $ - $ - $ 614,283 Liabilities: Warrant liabilities $ - $ - $ - $ - Embedded conversion option $ - $ - $ - $ - The Level 1 at fair value in the above table are classified as cash and cash equivalents in the accompanying consolidated balance sheets. We did not have any transfers between Level 1, 2, 3 2016 2015. following tables set forth a summary of changes in the fair value of Level 3 Predecessor Balance at January 1, 2015 Established in 2015 Change in Fair Value Balance at December 31, 2015 Description Liabilities: Embedded conversion option $ 4,362,225 $ - $ (4,362,225 ) $ - Warrant liabilities $ 25,484,596 $ - $ (25,484,596 ) $ - Predecessor Balance at January 1, 2016 Established in 2016 Change in Fair Value Balance at May 4, 2016 Description Liabilities: Embedded conversion option $ - $ - $ - $ - Warrant liabilities $ - $ - $ - $ - The Predecessor Company had no other financial assets and liabilities measured at fair value on a nonrecurring basis. Predecessor Company Non-Financial Assets and Liabilities Measured at Fair Value The Predecessor Company ’s property and equipment and intangible assets were measured at fair value on a non-recurring basis, upon impairment. As of September 30, 2015, $22.6 $1.1 third 2015. In determining the fair value of our intangibles assets, we assessed how our net tangible assets, goodwill and other intangible assets would b e valued in a hypothetical sale of the Company, with the sales price being equal to our market capitalization as of September 30, 2015. first second

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 14 – Commitments and Contingencies Successor Company Commitments and Contingencies As of t he Effective Date, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Recapitalization Investors. The Registration Rights Agreement provides certain resale registration rights to the Investors with respect to securities received in the Recapitalization Financing. Pursuant to the Registration Rights Agreement, the Company filed a registration statement with the U.S. Securities and Exchange Commission that went effective on January 11, 2017, Our primary office and warehouse facilities are located in Gaithersburg, Maryland, and comprise approximately 12,000 two s with monthly rent, including our share of certain annual operating costs and taxes, at approximately $14,000 $4,000 September 2019. 2,100 $4,000 April 30, 2018. 16,300 one $21,000 December 31, 2018. 401 July 31, 2014, August 1, 2014. $14,000 December 31, 2018. Future mini mum lease payments under operating leases are as follows: Years ending December 31: 2017 $ 463,000 2018 441,000 2019 122,000 Total future minimum lease payments $ 1,026,000 For the period from January 1, 2016 May 4, 2016, May 5, 2016 December 31, 2016, December 31, 2015, $87,000, $180,000, $224,000, In J uly 2009, $50,000,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Liquidity, Policy [Policy Text Block]	Liquidity Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, lack of operating history, and uncertainty of future profitability and pos sible fluctuations in financial results. Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, and executing licensing arrangements, and to a lesser extent by generating royalties and product revenues. We have incurred, and continue to incur, recurring losses and negative cash flows. On the Effective Date, the obligations of the Company under the Deerfield Facility Agreement and the DIP Credit Agreement were cancelled and the Company ceased to have any obligations thereunder. At December 31, 2016, $2.6 The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. After our emergence from bankruptcy on May 5, 2015, combined with the $3.0 June 30, 2017, March 2018. However, if we are unable to increase our revenues significantly or control our costs as effectively as expected, then we may second third 2017, December 31, 2017, additional capital beyond the Backstop Commitment More specifically, if we are unable to increase revenues or control costs in this manner, we may may We believe, based on the operating cash requirements and capital expenditures expected for 2017, cash on hand at December 31, 2016, $3.0 11 Equity and Stock-Based Compensation ), which is available June 30, 2017 , is adequate to fund operations for at least twelve As noted in Note 2 – Fresh Start Accounting
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been p repared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Upon emergence from bankruptcy on the Effective Date, the Company applied fresh start accounting, resulting in the Company becoming a new entity for financial reporting purposes (see Note 2 Fresh Start Accounting May 5, 2016
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned and controlled subsidiary Aldagen, Inc. (“ Aldagen”). All significant inter-company accounts and transactions are eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and l iabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the application of fresh start accounting, stock-based compensation, allowance for inventory obsolescence, allowance for doubtful accounts, valuation of derivative liabilities, contingent liabilities, fair value and depreciable lives of long-lived assets (including property and equipment, intangible assets and goodwill), deferred taxes and associated valuation allowance and the classification of our long-term debt. Actual results could differ from those estimates.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Concentration We generate accounts receivable from th e sale of our products. Specific customer receivables balances in excess of 10% December 31, 2016 December 31, 2015 Successor Predecessor December 31, 2016 December 31, 2015 Customer A 58 % 47 % Customer B 10 % 21 % Revenue from significant customers exceeding 10% Period from May 5, 2016 through December 31, 2016 Period from January 1, 2016 through May 4, 2016 Year ended December 31, 2015 Successor Predecessor Predecessor Customer B $ - $ 78% $ 67% Customer C - - 26% Customer D 22% - - Customer E 16% - - Historically, we used single suppliers for several components of the Aurix™ product line. We outsource the manufacturing of various products to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is no assurance that one
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents We consider all highly liquid instruments purchased with an original maturity of three to be cash equivalents. Cash and cash equivalents potentially subject us to a concentration of credit risk, as approximately $2.4 $250,000 December 31, 2016.
Receivables, Policy [Policy Text Block]	Accounts Receivables We generate accounts receivables from the sale of our products. We provide for an allowanc e against receivables for estimated losses that may December 31, 2016 2015, $409,000 $97,000, December 31, 2016.
Inventory, Policy [Policy Text Block]	Inventory Our inventory is produced by third first first ut basis and is stated at the lower of cost or net realizable value. We maintain an inventory of kits, reagents, and other disposables that have shelf-lives that generally range from 18 two As of December 31, 2016, of $18,123 $59,798 December 31, 2015, $115,792 $196,500 We provide for an allowance against inventory for estimated losses that may ’s remaining shelf-life and our anticipated ability to sell such inventory, which is estimated using historical usage and future forecasts, within its remaining shelf life. At December 31, 2016 2015, $8,000 $58,000,
Property, Plant and Equipment, Policy [Policy Text Block]	P roperty and Equipment Property and equipment is stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over its estimated useful life ranging from one four four six three six Ce ntrifuges may Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may rability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and Other Intangible Assets Predecessor intangible assets and goodwill In the Predecessor Company financial statements, intangible assets were acquired as part of our acquisition of the Angel business and Aldagen, and consisted of definite-lived and indefinite-lived intangibl e assets, including goodwill. During the quarter ended September 30, 2015, $22.6 September 30, 2015, $1.1 zero. December 31, 2015, In conjunction with the application of fresh start accounting, all remaining definite lived intangible assets were written off as of the Effective Date (See Note 2 – Fresh Start Accounting Successor intangible assets and goodwill In the Successor Company financial statements, intangible assets were established as part of fresh start accounting and relate to trademarks, technology, clinician relationships, and goodwill (see Note 2 – Fresh Start Accounting Our definite-lived intangible assets include trademarks, technology (including patents), and clinician relationships, and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstance s indicate that the carrying amount of the asset may Goodwill represents the excess of reorganization value over the fair value of tangible and identifiable intangib le assets and the fair value of liabilities as of the Effective Date. Goodwill is not amortized, but is subject to periodic review for impairment. Goodwill is reviewed annually, as of October 1, one Before employing detailed impairment testing methodologies, we first ive factors relevant to our reporting unit. When performing the qualitative assessment, we evaluate events and circumstances that would affect the significant inputs used to determine the fair value of the goodwill. Events and circumstances evaluated include: macroeconomic conditions that could affect us, industry and market considerations for the medical device industry that could affect us, cost factors that could affect our performance, our financial performance (including share price), and consideration of any company specific events that could negatively affect us, our business, or the fair value of our business. If we determine that it is more likely than not that goodwill is impaired, we will then apply detailed testing methodologies. Otherwise, we will conclude that no impairment has occurred. Detailed impairment testing involves comparing the fair value of our one l impairment has occurred. If the carrying value of the reporting unit exceeds its fair value, a second second one one one Successor Company intangible assets and goodwill were not impaired as of December 31, 2016.
Conditionally Redeemable Common Stock, Policy [Policy Text Block]	Co nditionally Redeemable Common Stock The Maryland Venture Fund (“ MVF,” part of Maryland Department of Business and Economic Development) had an investment in the Predecessor Company’s common stock, and could have required us to repurchase the common stock, at MVF’s option, upon certain events outside of our control. MVF’s common stock was classified as “contingently redeemable common shares” in the Predecessor Company’s accompanying consolidated balance sheets. The contingently redeemable common shares were cancelled as of the Effective Date.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition – Successor Company We recognize revenue when the four (1) (2) been rendered; (3) (4) We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recogni zed upon shipment of products to the customers. We do not maintain a reserve for returned products, as in the past those returns have not been material and are not expected to be material in the future. Percentage-based fees on licensee sales of covered products are generally recorded as products are sold by licensees, and are reflected as royalties in the consolidated statements of operations. Direct costs associated with product sales and royalty revenues are recorded at the time that revenue is recognized. Revenue Recognition – Predecessor Company The Predecessor Company provided for the sale of our products, including disposable processing sets and supplies to customers, and to Arthrex as distributor of the Angel product line. Revenue from the sale of pr oducts was recognized upon shipment. Usage or leasing of blood separation equipment As a result of the acquisition of the Angel business, we acquired various multiple element revenue arrangements that combined the (i) usage or leasing of blood separation processing equipment, (ii) maintenance of processing equipment, and (iii) purchase of disposable processing sets and supplies. We assigned these multiple element revenue arrangements to Arthrex in 2013 Deferred revenue at December 31, 2015 ted of prepaid licensing revenue of approximately $1.0 $0.1 $0.14 January 1, 2016 May 4, 2016. $0.4 December 31, 2015. License Agreement with Rohto The Company ’s license agreement with Rohto (See Note 4 – Distribution, Licens ing and Collaboration Arrangements $3.0 three March 31, 2015.
Segment Reporting, Policy [Policy Text Block]	Segments and Geographic Information Approximately 11% 22% January 1, 2016 May 4, 2016 May 5, 2016 December 31, 2016, ximately 31% December 31, 2015. one
Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]	Exit Activities and Realignment In May 2014, COVER-Stroke Phase 2 401. 401 $0.2 December 31, 2016 2015. On August 11, 2015, the Board of Directors approved our realignment plan with the goal of preserving and maximizing, for the benefit of our stockholders, the value of our existing assets. The plan eliminated approximately 30% December 4, 2015, 22% seven January 2016, four $0.9 December 31, 2015. $0.5 four January 2016 January 1, 2016 May 4, 2016. $0.5 four January January 1, 2016 May 4, 2016, $0.2 $0.2 $0.4 December 31, 2015. December 31, 2016 $0.3 December 31, 2015).
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Prior to the Effective Date, the Company, from time to time, issued stock options or stock awards to employees, directors, consultants, and other service providers under its 2002 LTIP”) or 2013 11 – Equity and Stock-Based Compensation All outstanding stock options were cancelled as of the Effective Date. In July 2016, August 2016 2016 “2016 November 21, 2016, 2016 2016, 1,370 ,000 The fair value of employee stock options is measured at the date of grant. Expected volatilities for the 2016 five zero. 2016 2015 Risk free rate 1.8 - 2.0% 1.4 - 1.7% Weighted average expected years until exercise 4.8 - 6.0 6.3 Expected stock volatility 83% 93 - 117% Dividend yield - - Stock-based compensation for awards granted to non-employees is periodically re-measured as the underlying awards vest. The Company recognizes an expense for such awards throughout the performance period as the services are provided by the non-employees, based on the fair value of these options and warrants at each reporting period. The fair value of stock options and compensatory warrants issued to service providers utilizes the same methodology with the exception of the expected term. For awards to non-employees, the Company estimates that the options or warrants will be held for the full term.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. All of our tax years remain subject to examination by the tax authorities. For the year ended December 31, 2015, elates exclusively to a deferred tax liability associated with the amortization for tax purposes of the Predecessor Company’s goodwill. The deferred tax liability was eliminated in the third 2015 The Company ’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no such items in 2016 2015.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Earnings (Loss) per Share Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding (includ ing contingently issuable shares when the contingencies have been resolved) during the period. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is a nti-dilutive. For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding (including contingently issuable shares when the contingencies have been resolved) plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible debt using the if-converted method. All of the Company ’s outstanding stock options and warrants were considered anti-dilutive for the periods from January 1, 2016 May 4, 2016, May 5, 2016 December 31, 2016, December 31, 2015. January 1, 2016 May 4, 2016. Period from May 5, 2016 Period from January 1, 2016 Year ended December 31, 2015 Successor Predecessor Predecessor Shares underlying: Common stock options 1,265,000 9,173,119 11,069,166 Stock purchase warrants 6,180,000 113,629,178 116,034,682 Convertible debt - - 73,342,730 Earnings (loss) per share are calculated for basic and diluted earnings per share as follows: Period from May 5, 2016 Period from January 1, 2016 Year ended December 31, 2015 Successor Predecessor Predecessor Numerator for basic income (loss) per share $ (5,695,027 ) $ 28,173,934 $ (52,808,108 ) Numerator adjustment for potential dilutive securities - 172,546 - Numerator for diluted income (loss) per share (5,695,027 ) 28,346,480 (52,808,108 ) Denominator for basic income (loss) per share weighted average outstanding common shares 9,895,966 125,951,100 125,951,100 Dilutive effect of convertible debt - 67,307,692 - Denominator for diluted income (loss) per share weighted average outstanding common shares 9,895,966 193,258,792 125,951,100 Basic and diluted earnings (loss) per share Basic $ (0.58 ) $ 0.22 $ (0.42 ) Diluted $ (0.58 ) $ 0.15 $ (0.42 )
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In April 2015, FASB”) issued guidance as to whether a cloud computing arrangement (e.g., software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements) includes a software license and, based on that determination, how to account for such arrangements. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The amendment is effective for reporting periods beginning after December 15, 2015, may January 1, 2016; In April 2015, a direct deduction from the carrying amount of that debt liability, in the same manner as debt discounts, rather than as an asset. The standard is effective for reporting periods beginning after December 15, 2015, January 1, 2016; In September 2015, lting from business combinations. Under the guidance, an acquirer will be required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined. The guidance requires an entity to present separately on the face of the income statement, or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date. The standard is effective for reporting periods beginning after December 15, 2015. January 1, 2016; In August 2014, ’s ability to continue as a going concern. Under U.S. GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Previously, there was no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. This was issued to provide guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this update are effective for the annual period ending after December 15, 2016, December 31, 2016; Unadopted Accounting Pronouncements In May 2014, ASB issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five 1) 2) 3) 4) 5) August 2015, one December 15, 2017, December 15, 2016. March 2016, April 2016, May 2016, two March 3, 2016 May 2016, In Jul y 2015, 330 December 15, 2016, In November 2015, to current and noncurrent amounts. Under this guidance, deferred tax liabilities and assets will be classified as noncurrent amounts. The standard is effective for reporting periods beginning after December 15, 2016. In February 2016, long-term leases on the balance sheet, and expands disclosure requirements regarding leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018, In March 2016, or, and financial statement disclosure of, stock-based compensation awards. Under the guidance, all excess tax benefits and tax deficiencies related to stock-based compensation awards are to be recognized as income tax expenses or benefits in the income statement, and excess tax benefits should be classified along with other income tax cash flows in the operating activities section of the statement of cash flows. Under the guidance, companies can also elect to either estimate the number of awards that are expected to vest, or account for forfeitures as they occur. In addition, the guidance amends some of the other stock-based compensation awards guidance to more clearly articulate the requirements and cash flow presentation for withholding shares for tax-withholding purposes. The guidance is effective for reporting periods beginning after December 15, 2016, In March 2016, debt hosts. The amendments of this guidance are effective for reporting periods beginning after December 15, 2016, In June 2016, financial instruments, including trade receivables. The guidance eliminates the probable initial recognition threshold that was previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity's current estimate of all future expected credit losses. Under the previous guidance, an entity only considered past events and current conditions. The guidance is effective for fiscal years beginning after December 15, 2019. December 15, 2018. In August 2016, the FASB issued guidance on the classification of certain cash receipts and cash payments in the statement of cash flows, including those related to debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance, and distributions received from equity method investees. The guidance is effective for fiscal years beginning after December 15, 2017. may In November 2016, e requires that amounts generally described as restricted cash and restricted cash equivalents be included in cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the statement of cash flows. The guidance is effective for the fiscal years beginning after December 15, 2017. In January 2017, 2 fair value of goodwill under Step 2, zero 2 December 15, 2021. January 1, 2017. In January 2017, December 15, 2018. We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our results of operations, financial position, or cash flows.

Note 2 - Fresh Start Accounti22

Note 2 - Fresh Start Accounting (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Allocated Determined Reorganization Value [Table Text Block]	Enterprise Value $ 17,889 Plus estimated fair value of liabilities 6,161 Reorganization Value 24,050 Less: Estimated fair value of tangible assets (13,574 ) Estimated fair value of identifiable intangible assets (8,397 ) Goodwill $ 2,079
Schedule of Fresh-Start Adjustments [Table Text Block]	Predecessor Company Reorganization Adjustments Fresh Start Adjustments Successor Company ASSETS Current assets Cash and cash equivalents $ 3,305,709 $ 7,052,500 (1) $ 10,358,209 Restricted cash 53,463 53,463 Accounts and other receivable, net 1,288,445 1,288,445 Inventory, net 56,348 56,348 Prepaid expenses and other current assets 611,593 $ (16,053 )(b) 595,540 - Total current assets 5,315,558 (16,053 ) 7,052,500 12,352,005 Property and equipment, net 865,716 865,716 Deferred costs and other assets 355,741 355,741 Intangible assets, net 2,406,457 (2,406,457 )(a) 8,397,000 (2) 8,397,000 Goodwill - 2,079,284 (2) 2,079,284 TOTAL ASSETS $ 8,943,472 $ (2,422,510 ) $ 17,528,784 $ 24,049,746 LIABILITIES AND EQUITY (DEFICIT) Current liabilities not subject to compromise Accounts payable $ 2,877,170 $ 2,877,170 Accrued expenses and liabilities 3,112,244 3,112,244 Accrued interest - - Deferred revenue, current portion 899,920 $ (899,920 )(c) - Convertible debt subject to put rights - - Short term debtor-in-possession note payable 5,750,000 (5,750,000 )(d) - Total current liabilities not subject to compromise 12,639,334 (6,649,920 ) - 5,989,414 Non-current liabilities not subject to compromise Deferred revenue - - Other liabilities 171,613 171,613 Total non-current liabilities not subject to compromise 171,613 - - 171,613 Liabilities subject to compromise Accounts payable 214,554 (214,554 )(e) - Accrued expenses and liabilities 559,202 (559,202 )(e) - Accrued interest 3,316,121 (3,316,121 )(d) - Deferred revenue - - Convertible debt subject to put rights 35,000,000 (35,000,000 )(d) - Derivative liabilities - - Other liabilities - - Total liabilities subject to compromise 39,089,877 (39,089,877 ) - - TOTAL LIABILITIES 51,900,824 (45,739,797 ) - 6,161,027 Conditionally redeemable common stock 500,000 (500,000 )(f) - Common stock outstanding, at par 12,477 (12,477 )(f) 750 (1) 750 Common stock issuable 392,950 (392,950 )(f) - Preferred stock outstanding, at par - 3 (3) 3 Additional paid-in capital 126,011,808 (126,011,808 )(f) 17,887,966 (4) 17,887,966 Retained earnings (accumulated deficit) (169,874,587 ) 170,234,522 (g) (359,935 )(5) - TOTAL EQUITY (DEFICIT) (43,457,352 ) 43,817,287 17,528,784 17,888,719 TOTAL LIABILITIES AND EQUITY (DEFICIT) $ 8,943,472 $ (2,422,510 ) $ 17,528,784 $ 24,049,746
Schedule of Cumulative Reorganization Adjustments [Table Text Block]	Description Adjustment Amount Elimination of existing intangible assets (a) $ (2,406,457 ) Elimination of prepaid Angel expenses (b) (16,053 ) Elimination of Angel deferred revenue (c) 899,920 Termination of debt agreements and accrued interest (d) 44,066,121 Elimination of various payables and accruals (e) 773,756 Cancellation of existing equity (f) 126,917,235 $ 170,234,522
Fresh Start Adjustments, Schedule of Allocated Determined Reorganzation Value [Table Text Block]	Enterprise Value $ 17,889 Plus estimated fair value of liabilities 6,161 Reorganization Value 24,050 Less: Estimated fair value of tangible assets (13,574 ) Estimated fair value of identifiable intangible assets (8,397 ) Goodwill $ 2,079
Cumulative Impact of Fresh Start Adjustments on Additional Paid in Capital [Table Text Block]	Description Adjustment Amount Cash proceeds from issuance of common stock (1) $ 7,052,500 Establishment of intangible assets (2) 10,476,284 Net assets of the predecessor (5) 359,935 Less par value of common and preferred stock (3) (753 ) $ 17,887,966
Schedule of Reorganization Costs [Table Text Block]	Period from May 5, 2016 through December 31, 2016 Period from January 1, 2016 through May 4, 2016 Successor Predecessor Professional fees $ 324,551 $ 3,598,216 Net gain on reorganization adjustments - (34,869,566 ) Reorganization items, net $ 324,551 $ (31,271,350 ) Cash payments for reorganization items $ 1,507,863 $ 1,839,560

Note 3 - Liquidity and Summar23

Note 3 - Liquidity and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Successor Predecessor December 31, 2016 December 31, 2015 Customer A 58 % 47 % Customer B 10 % 21 % Period from May 5, 2016 through December 31, 2016 Period from January 1, 2016 through May 4, 2016 Year ended December 31, 2015 Successor Predecessor Predecessor Customer B $ - $ 78% $ 67% Customer C - - 26% Customer D 22% - - Customer E 16% - -
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2016 2015 Risk free rate 1.8 - 2.0% 1.4 - 1.7% Weighted average expected years until exercise 4.8 - 6.0 6.3 Expected stock volatility 83% 93 - 117% Dividend yield - -
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Period from May 5, 2016 Period from January 1, 2016 Year ended December 31, 2015 Successor Predecessor Predecessor Shares underlying: Common stock options 1,265,000 9,173,119 11,069,166 Stock purchase warrants 6,180,000 113,629,178 116,034,682 Convertible debt - - 73,342,730
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Period from May 5, 2016 Period from January 1, 2016 Year ended December 31, 2015 Successor Predecessor Predecessor Numerator for basic income (loss) per share $ (5,695,027 ) $ 28,173,934 $ (52,808,108 ) Numerator adjustment for potential dilutive securities - 172,546 - Numerator for diluted income (loss) per share (5,695,027 ) 28,346,480 (52,808,108 ) Denominator for basic income (loss) per share weighted average outstanding common shares 9,895,966 125,951,100 125,951,100 Dilutive effect of convertible debt - 67,307,692 - Denominator for diluted income (loss) per share weighted average outstanding common shares 9,895,966 193,258,792 125,951,100 Basic and diluted earnings (loss) per share Basic $ (0.58 ) $ 0.22 $ (0.42 ) Diluted $ (0.58 ) $ 0.15 $ (0.42 )

Note 5 - Receivables (Tables)

Note 5 - Receivables (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	Successor Predecessor December 31, December 31, 2016 2015 Trade receivables $ 100,660 $ 460,763 Other receivables 603,015 650,230 703,675 1,110,993 Less allowance for doubtful accounts (409,377 ) (96,748 ) $ 294,298 $ 1,014,245

Note 6 - Property and Equipme25

Note 6 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	Successor Predecessor December 31, December 31, 2016 2015 Medical equipment $ 405,096 $ 1,195,467 Office equipment 48,888 142,827 Software 257,619 523,571 Manufacturing equipment 34,899 307,851 Leasehold improvements 19,215 32,130 765,717 2,201,846 Less accumulated depreciation and amortization (279,601 ) (1,086,632 ) $ 486,116 $ 1,115,214

Note 7 - Goodwill and Other I26

Note 7 - Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	Successor Predecessor December 31, December 31, 2016 2015 Trademarks $ 917,000 $ 1,047,000 Technology 6,576,000 2,355,000 Customer and clinician relationships 904,000 708,000 8,397,000 4,110,000 Accumulated amortization trademarks (39,934 ) (184,981 ) Accumulated amortization technology (477,290 ) (902,750 ) Accumulated amortization customer and clinician relationships (39,368 ) (508,875 ) (556,592 ) (1,596,606 ) $ 7,840,408 $ 2,513,394
Schedule of Goodwill [Table Text Block]	Successor Predecessor Balance, at December 31, 2014 $ - $ 1,128,517 2015 impairment - (1,128,517 ) Balance, at December 31, 2015 - $ - Fresh start accounting 2,079,284 Balance, at December 31, 2016 $ 2,079,284
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2017 $ 852,000 2018 852,000 2019 852,000 2020 852,000 2021 852,000 Thereafter 3,580,000

Note 8 - Accrued Liabilities (T

Note 8 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	Successor Predecessor December 31, December 31, 2016 2015 Customer deposits $ 72,192 $ 611,341 Accrued compensation and benefits 91,325 532,435 Other payables 124,484 518,734 Due to Arthrex - 31,785 Accrued professional fees 213,116 190,787 Accrued loss on abandonment of lease, current portion 88,560 103,173 Accrued Angel machine rework costs 465,000 465,000 $ 1,054,677 $ 2,453,255

Note 11 - Equity and Stock-ba28

Note 11 - Equity and Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding Exercise Price Expiration Date Classification 20,000 $0.40 June 2016 Equity 136,364 $0.66 February 2018 Equity 6,363,638 $0.75 February 2018 Equity 5,047,461 $0.65 December 2017 Equity 232,964 $0.65 December 2017 Equity 2,884,615 $0.52 March 2019 Liability 1,474,615 $0.52 March 2019 Liability 3,525,000 $0.52 June 2019 Liability 1,079,137 $0.70 February 2020 Equity 250,000 $0.70 February 2020 Equity 25,115,384 $0.52 March 2021 Liability 67,500,000 $0.52 June 2021 Liability 113,629,178
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock Options – Incentive Plans Shares Weighted- Average Weighted- Average Aggregate Intrinsic Outstanding at January 1, 2016 11,069,166 $ 0.78 6.1 $ - Granted - $ - $ - Exercised - $ - $ - Forfeited or expired (11,069,166 ) $ 0.78 $ - Outstanding at May 4, 2016 - $ - - $ - Exercisable at May 4, 2016 - $ - - $ - Vested and expected to vest at May 4, 2016 - $ - - $ - Stock Options – 2016 Omnibus Plan Shares Exercise Weighted- Average Aggregate Intrinsic Outstanding at May 5, 2016 - $ - - $ - Granted 1,370,000 $ 1.00 10.00 $ - Exercised - Forfeited or expired (105,000 ) $ - Outstanding at December 31, 2016 1,265,000 $ 1.00 9.51 $ - Exercisable at December 31, 2016 331,665 $ 1.00 9.51 $ - Vested and expected to vest at December 31, 2016 1,265,000 $ 1.00 9.51 $ -
Schedule of Stockholders' Equity Note, Warrants or Rights Issued for Services [Table Text Block]	Warrants to Service Providers Shares Weighted- Average Weighted- Average Aggregate Intrinsic Outstanding at January 1, 2016 406,364 $ .67 3.3 $ - Granted - $ - $ - Exercised - $ - $ - Forfeited or expired (406,364 ) $ .67 $ - Outstanding at May 4, 2016 - $ - $ - Exercisable at May 4, 2016 - $ - $ -
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Number of Average Exercise Outstanding Remaining Exercise Number Exercise Price Shares Contract Life Price Exercisable Price $1.00 1,265,000 9.51 $ 1.00 331,665 1.00
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	Period from May 5, 2016 Period from January 1, 2016 Year Ended December 31, 2015 Successor Predecessor Predecessor Sales and marketing $ 8,963 $ 18,504 $ 156,297 Research and development 9,769 6,858 74,989 General and administrative 56,267 29,719 551,469 $ 74,999 $ 55,081 $ 782,755

Note 12 - Income Taxes (Tables)

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Period from May 5, 2016 through December 31, 2016 Period from January 1, 2016 through May 4, 2016 Year Ended December 31, 2015 Successor Predecessor Predecessor Current: Federal $ - $ - $ - State - - - Deferred: Federal 1,989,763 (9,836,756 ) 29,084,623 State 236,490 (2,237,382 ) 3,614,773 Change in valuation allowance (2,226,253 ) 12,074,138 (32,610,383 ) Total Benefit for Income Taxes $ - $ - $ 89,013
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2016 December 31, 2015 Successor Predecessor Deferred tax assets: Stock-based compensation $ 29,379 $ 6,238,000 Tax credits 3,484,799 3,339,000 Deferred revenue - 462,000 Start-up and organizational costs 270,652 275,000 Tax deductible Goodwill 354,831 404,000 Property and equipment 163,755 207,000 Other 224,910 283,000 Total deferred tax assets 4,528,326 11,208,000 Deferred tax liabilities: Intangible Assets (2,374,950 ) (114,000 ) Total deferred tax liabilities (2,374,950 ) (114,000 ) Net deferred tax assets, excluding net operating loss carryforwards 2,153,376 11,094,000 Net operating loss carryforwards 50,713,527 61,076,000 52,866,903 72,170,000 Less valuation allowance (52,866,903 ) (72,170,000 ) Total deferred tax assets (liabilities) $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Period from May 5, 2016 through December 31, 2016 Period from January 1, 2016 through May 4, 2016 Year Ended December 31, 2015 Successor Predecessor Predecessor U.S. federal statutory income tax 35.0 35.0 % 35.0 % State and local income tax, net of benefits 4.2 4.2 % 4.8 % Fair value of derivatives - - 22.4 % Other (0.1 )% 3.7 % (0.4 )% Valuation allowance for deferred income tax assets (39.1 )% (42.9 )% (61.6 )% Effective income tax rate - % - % 0.2 %

Note 13 - Fair Value Measurem30

Note 13 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Identifiable Intangible Asset Valuation Method Significant Unobservable Inputs Estimated Fair Value Trademarks Income approach - royalty savings method Projected sales $ 917,000 Estimated royalty rates Discount rate Technology Income approach - royalty savings method Projected sales $ 6,576,000 Estimated royalty rates Discount rate Clinician Relationships Income approach - excess earnings method Projected sales $ 904,000 Estimated attrition Projected margins Discount rate
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of December 31, 2015 Level 1 Level 2 Level 3 Total Assets - money market funds $ 614,283 $ - $ - $ 614,283 Liabilities: Warrant liabilities $ - $ - $ - $ - Embedded conversion option $ - $ - $ - $ -
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Predecessor Balance at January 1, 2015 Established in 2015 Change in Fair Value Balance at December 31, 2015 Description Liabilities: Embedded conversion option $ 4,362,225 $ - $ (4,362,225 ) $ - Warrant liabilities $ 25,484,596 $ - $ (25,484,596 ) $ - Predecessor Balance at January 1, 2016 Established in 2016 Change in Fair Value Balance at May 4, 2016 Description Liabilities: Embedded conversion option $ - $ - $ - $ - Warrant liabilities $ - $ - $ - $ -

Note 14 - Commitments and Con31

Note 14 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Years ending December 31: 2017 $ 463,000 2018 441,000 2019 122,000 Total future minimum lease payments $ 1,026,000

Note 1 - Description of Busin32

Note 1 - Description of Business and Bankruptcy Proceedings (Details Textual)	Jun. 20, 2016USD ($)shares	May 05, 2016USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2014shares	May 04, 2016$ / shares	Dec. 31, 2015$ / shares
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001
Payment for Offering Cost | $		$ 100,000
Warrant, Expiration Date		May 5, 2021
Class of Warrant or Right, Date from which Warrants or Rights Exercisable		Nov. 5, 2016
Preferred Stock, Shares Authorized			1,000,000	1,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares			$ 0.0001	$ 0.0001
Preferred Stock, Liquidation Preference, Value | $			$ 29,038,000	$ 29,038,000
Arthrex [Member]
Reduction in Allowed Claim | $		$ 15,000,000
Series A Preferred Stock [Member]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.0001
Stock Issued During Period, Shares, New Issues		29,038
Preferred Stock, Shares Authorized		29,038
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 0.0001
Preferred Stock, Liquidation Preference, Value | $		$ 29,038,000
Number of Board Members Nominated and Elected by Shareholders		1
Preferred Stock, Voting Rights, Number of Votes Per Share		5
Preferred Stock, Voting Rights, Percentage of Voting Rights of Capital Stock		1.00%
Common Stock [Member]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.0001
Stock Issued During Period, Shares, New Issues		7,500,000	2,264,612
Proceeds from Issuance of Common Stock | $		$ 7,300,000
Proceeds from Issuance of Common Stock, Net of Issuance Costs | $		$ 7,052,500
Stock Issued During Period, Shares, Other		200,000			2,709,677
Payment for Offering Cost | $		$ 100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		6,180,000
Warrant, Expiration Date		May 5, 2021
Class of Warrant or Right, Date from which Warrants or Rights Exercisable		Nov. 5, 2016
Backstop Commitment Date		Jun. 30, 2017
Commitment Fees for Debt | $		$ 250,000
Stock Issued During Period, Shares, Issued for Services			162,500
Common Stock [Member] | Backstop Commitment [Member]
Number of Shares Commited to Purchase		12,800,000
Value of Shares Commited to Purchase | $		$ 3,000,000
Common Stock [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.50
Common Stock [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 1
Exchange Shares [Member]
Stock Issued During Period, Shares, New Issues		2,264,612
Number of Shares Commited to Issue		3,000,000
Shares of Old Common Stock to New Common Stock, Conversion Ratio		41.8934
Administrative Claim Shares [Member]
Stock Issued During Period, Shares, New Issues	162,500
Stock Issued During Period, Shares, Issued for Services	100,000
Debt Conversion, Converted Instrument, Shares Issued	62,500
Debt Conversion, Original Debt, Amount | $	$ 62,500
Platelet Rich Plasma (PRP) [Member]
Number of Products Produced				2

Note 2 - Fresh Start Accounti33

Note 2 - Fresh Start Accounting (Details Textual) - USD ($)	May 05, 2016	Dec. 31, 2016	May 04, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Reorganization Value	$ 24,050,000
Debt-free Net Cash Flow Growth Rate	3.40%
Fair Value Inputs, Discount Rate	29.00%
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001	$ 0.0001
Intangible Assets, Net (Excluding Goodwill)	$ 8,400,000	$ 7,840,408
Goodwill	$ 2,100,000	2,079,284		$ 0	$ 0	$ 0
Preferred Stock, Liquidation Preference, Value		$ 29,038,000
Warrant, Expiration Date	May 5, 2021
Class of Warrant or Right, Date from which Warrants or Rights Exercisable	Nov. 5, 2016
Series A Preferred Stock [Member]
Common Stock, Par or Stated Value Per Share	$ 0.0001
Stock Issued During Period, Shares, New Issues	29,038
Preferred Stock, Liquidation Preference, Value	$ 29,038,000
Common Stock [Member]
Common Stock, Par or Stated Value Per Share	$ 0.0001
Stock Issued During Period, Shares, New Issues	7,500,000	2,264,612
Proceeds from Issuance of Common Stock, Net of Issuance Costs	$ 7,052,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	6,180,000
Warrant, Expiration Date	May 5, 2021
Class of Warrant or Right, Date from which Warrants or Rights Exercisable	Nov. 5, 2016
Backstop Commitment Date	Jun. 30, 2017
Common Stock [Member] | Backstop Commitment [Member]
Number of Shares Commited to Purchase	12,800,000
Value of Shares Commited to Purchase	$ 3,000,000
Common Stock [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.50
Common Stock [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1
Revaluation of Assets [Member]
Reorganization Value	$ 17,889,000

Note 2 - Fresh Start Accounti34

Note 2 - Fresh Start Accounting - Reorganization Value (Details)	May 05, 2016USD ($)
Reorganization Value	$ 24,050,000
Estimated fair value of tangible assets	(13,574,000)
Estimated fair value of identifiable intangible assets	(8,397,000)
Goodwill	2,079,284
Revaluation of Assets [Member]
Reorganization Value	17,889,000
Revaluation of Liabilities [Member]
Reorganization Value	$ 6,161,000

Note 2 - Fresh Start Adjustment

Note 2 - Fresh Start Adjustments - Fresh Start Adjustments (Details) - USD ($)		Dec. 31, 2016	May 05, 2016
Cash and cash equivalents, predecessor company			$ 3,305,709
Cash and cash equivalents, fresh start adjustments	[1],[2]		7,052,500
Cash and cash equivalents, successor company			10,358,209
Restricted cash, predecessor company			53,463
Restricted cash, successor company			53,463
Accounts and other receivable, net, predecessor company			1,288,445
Accounts and other receivable, net, successor company			1,288,445
Inventory, net, predecessor company			56,348
Inventory, net, successor company			56,348
Prepaid expenses and other current assets, predecessor company			611,593
Prepaid expenses and other current assets, reorganization adjustments	[3],[4]		(16,053)
Prepaid expenses and other current assets, successor company			595,540
Total current assets, predecessor company			5,315,558
Total current assets, reorganization adjustments			(16,053)
Total current assets, fresh start adjustments			7,052,500
Total current assets, successor company			12,352,005
Property and equipment, net, predecessor company			865,716
Property and equipment, net, successor company			865,716
Deferred costs and other assets, predecessor company			355,741
Deferred costs and other assets, successor company			355,741
Intangible assets, net, predecessor company			2,406,457
Intangible assets, net, reorganization adjustments	[5],[6]		(2,406,457)
Intangible assets, net, fresh start adjustments	[7]		8,397,000
Intangible assets, net, successor company			8,397,000
Goodwill, predecessor company			0
Goodwill, fresh start adjustments		$ 2,079,284	2,079,284	[7]
Goodwill			2,079,284
TOTAL ASSETS, predecessor company			8,943,472
TOTAL ASSETS, reorganization adjustments			(2,422,510)
TOTAL ASSETS, fresh start adjustments			17,528,784
TOTAL ASSETS, successor company			24,049,746
Reorganization Adjustment, Increase (Decrease), Deferred Revenue, Current Portion	[8]		(899,920)
Total liabilities subject to compromise, predecessor company			39,089,877
Total liabilities subject to compromise, reorganization adjustments			(39,089,877)
Total liabilities subject to compromise, successor company			0
TOTAL LIABILITIES, predecessor company			51,900,824
TOTAL LIABILITIES, reorganization adjustments			(45,739,797)
TOTAL LIABILITIES, successor company			6,161,027
Conditionally redeemable common stock, predecessor company			500,000
Conditionally redeemable common stock, reorganization adjustments	[9]		(500,000)
Conditionally redeemable common stock, successor company			0
Common stock outstanding, at par, predecessor company			12,477
Common stock outstanding, at par, reorganization adjustments	[9]		(12,477)
Common stock outstanding, at par, fresh start adjustments	[1]		750
Common stock outstanding, at par, successor company			750
Common stock issuable, predecessor company			392,950
Common stock issuable, reorganization adjustments	[9]		(392,950)
Common stock issuable, successor company			0
Preferred stock outstanding, at par, predecessor company			0
Preferred stock outstanding, at par, fresh start adjustments	[10]		3
Preferred stock outstanding, at par, successor company			3
Additional paid-in capital, predecessor company			126,011,808
Additional paid-in capital, reorganization adjustments	[9]		(126,011,808)
	[11]		17,887,966
Additional paid-in capital, successor company			17,887,966
Retained earnings (deficit), predecessor company			(169,874,587)
Retained earnings (deficit), reorganization adjustments	[12]		170,234,522
Retained earnings (deficit), fresh start adjustments	[13],[14]		(359,935)
Retained earnings (deficit), successor company			0
TOTAL EQUITY, predecessor company			(43,457,352)
TOTAL EQUITY, reorganization adjustments			43,817,287
TOTAL EQUITY, fresh start adjustments			17,528,784
TOTAL EQUITY, successor company			17,888,719
TOTAL LIABILITIES AND EQUITY, predecessor company			8,943,472
TOTAL LIABILITIES AND EQUITY, reorganization adjustments			(2,422,510)
TOTAL LIABILITIES AND EQUITY, fresh start adjustments			17,528,784
TOTAL LIABILITIES AND EQUITY, successor company			24,049,746
Liabilities Not Subject to Compromise [Member]
Accounts payable, predecessor company			2,877,170
Accounts payable, successor company			2,877,170
Accrued expenses and liabilities, predecessor company			3,112,244
Accrued expenses and liabilities, successor company			3,112,244
Accrued interest, predecessor company			0
Accrued interest, successor company			0
Deferred revenue, current portion, predecessor company			899,920
Reorganization Adjustment, Increase (Decrease), Deferred Revenue, Current Portion	[15]		(899,920)
Deferred revenue, current portion, successor company			0
Convertible debt subject to put rights, predecessor company			0
Convertible debt subject to put rights, successor company			0
Short term debtor-in-possession note payable, predecessor company			5,750,000
Short term debtor-in-possession note payable, reorganization adjustments	[16]		(5,750,000)
Short term debtor-in-possession note payable, successor company			0
Total current liabilities not subject to compromise, predecessor company			12,639,334
Total current liabilities not subject to compromise, reorganization adjustments			(6,649,920)
Total current liabilities not subject to compromise, successor company			5,989,414
Deferred revenue, predecessor company			0
Deferred revenue, successor company			0
Other liabilities, predecessor company			171,613
Other liabilities, successor company			171,613
Total non-current liabilities not subject to compromise, predecessor company			171,613
Total non-current liabilities not subject to compromise, successor company			171,613
Liabilities Subject to Compromise [Member]
Accounts payable, predecessor company			214,554
Accounts payable, successor company			0
Accrued expenses and liabilities, predecessor company			559,202
Accrued expenses and liabilities, successor company			0
Accrued interest, predecessor company			3,316,121
Accrued interest, successor company			0
Convertible debt subject to put rights, predecessor company			35,000,000
Convertible debt subject to put rights, successor company			0
Deferred revenue, predecessor company			0
Deferred revenue, successor company			0
Other liabilities, predecessor company			0
Other liabilities, successor company			0
Accounts payable, reorganization adjustments	[17]		(214,554)
Accrued expenses and liabilities, reorganization adjustments	[17]		(559,202)
Accrued interest, reorganization adjustments	[16]		(3,316,121)
Convertible debt subject to put rights, reorganization adjustments	[16]		(35,000,000)
Derivative liabilities, predecessor company			0
Derivative liabilities, successor company			$ 0
[1]	Pursuant to the Plan of Reorganization, as of the Effective Date, the Company issued 7,500,000 shares of New Common Stock, par value $0.0001 per share, to certain accredited investors for net cash to the Company of $7,052,500. The Company also issued Warrants to purchase 6,180,000 shares of New Common Stock to certain of the investors. The Warrants terminate on May 5, 2021 and are exercisable at any time on or after November 5, 2016 at exercise prices ranging from $0.50 per share to $1.00 per share. The number of shares of New Common Stock underlying a Warrant and its exercise price are subject to customary adjustments upon subdivisions, combinations, payment of stock dividends, reclassifications, reorganizations and consolidations. Certain investors also provided Backstop Commitments to purchase up to 12,800,000 additional shares of New Common Stock for an aggregate purchase price of up to $3,000,000. The Company cannot call the Backstop Commitment prior to June 30, 2017. The New Common Stock, Warrants and Backstop Commitment are classified as equity.
[2]	Pursuant to the Plan of Reorganization, as of the Effective Date, the Company issued 7,500,000 shares of new common stock, par value $0.0001 per share (the "New Common Stock"), to certain accredited investors for net cash to the Company of $7,052,500. The Company also issued warrants (the "Warrants") to purchase 6,180,000 shares of New Common Stock to certain of the investors. The Warrants terminate on May 5, 2021 and are exercisable at any time on or after November 5, 2016 at exercise prices ranging from $0.50 per share to $1.00 per share. The number of shares of New Common Stock underlying a Warrant and its exercise price are subject to customary adjustments upon subdivisions, combinations, payment of stock dividends, reclassifications, reorganizations and consolidations. Certain investors also provided backstop commitments (collectively, the "Backstop Commitment") to purchase up to 12,800,000 additional shares of New Common Stock for an aggregate purchase price of up to $3,000,000. The Company cannot call the Backstop Commitment prior to June 30, 2017. The New Common Stock, Warrants and Backstop Commitment are classified as equity.
[3]	Pursuant to the Plan of Reorganization, the Company assigned to Deerfield the Company's (i) rights, title and interest in and to its existing license agreement with Arthrex, (ii) the associated intellectual property owned by the Company and licensed under such agreement, and (iii) rights to collect royalty payments thereunder. As such, certain prepaid expenses related to the Angel business were eliminated.
[4]	Pursuant to the Plan of Reorganization, the Company assigned to Deerfield the Company's (i) rights, title and interest in and to its existing license agreement with Arthrex, (ii) the associated intellectual property owned by the Company and licensed under such agreement, and (iii) rights to collect royalty payments thereunder. As such, certain prepaid expenses related to the Angel business were eliminated.
[5]	As a result of fresh start accounting, all intangible assets existing as of the Effective Date were established at fair value. This adjustment eliminates the carrying value of previously existing intangible assets as of the Effective Date as the underlying Angel assets were assigned to Deerfield pursuant to the Plan of Reorganization.
[6]	As a result of fresh start accounting, all intangible assets existing as of the Effective Date were established at fair value. This adjustment eliminates the carrying value of previously existing intangible assets as of the Effective Date as the underlying Angel assets were assigned to Deerfield pursuant to the Plan of Reorganization.
[7]	Represents identifiable intangible assets of approximately $8.4 million and goodwill of approximately $2.1 million. Upon the application of fresh start accounting, the Company allocated the reorganization value to its individual assets based on their estimated fair values. Reorganization value represents the fair value of the Successor Company’s assets before considering liabilities, and the excess of reorganization value over the fair value of identified tangible and intangible assets is reported separately on the consolidated balance sheet as goodwill. The Company, with the assistance of external valuation specialists, estimated the enterprise value of the Company upon emergence from Chapter 11 bankruptcy to be $17.9 million. Enterprise value is defined as the total invested capital, which includes cash and cash equivalents. The estimate is based on a calculation of the present value of the projected future cash flows of the Company from May 5, 2016 through the year ending December 31, 2025 along with a terminal value. The Company estimated a terminal value using the Gordon Growth Model. In applying fresh start accounting, the Company followed these principles: ? The reorganization value, estimated as approximately $24.0 million, which represents the sum of the enterprise value and estimated fair value of noninterest bearing liabilities, was allocated to the Successor Company's assets based on their estimated fair values. The reorganization value exceeded the sum of the fair value assigned to the assets, and the excess was recognized as goodwill of the Successor Company as of May 5, 2016. ? Each liability existing as of May 5, 2016 has been stated at its estimated fair value. ? Deferred tax assets and liabilities have been recognized for differences between the assigned values and the tax basis of the recognized assets and liabilities, and have been fully valued as of May 5, 2016 to reduce deferred tax assets to the amounts expected to be realized. Pursuant to fresh start accounting the Company allocated the determined reorganization value to the Successor Company's assets as follows (in thousands): Enterprise Value $ 17,889 Plus estimated fair value of liabilities 6,161 Reorganization Value 24,050 Less: Estimated fair value of tangible assets (13,574 ) Estimated fair value of identifiable intangible assets (8,397 ) Goodwill $ 2,079
[8]	Pursuant to the Plan of Reorganization, the Company assigned to Deerfield the Company's (i) rights, title and interest in and to its existing license agreement with Arthrex, (ii) the associated intellectual property owned by the Company and licensed under such agreement, and (iii) rights to collect royalty payments thereunder. As such, all deferred revenue related to the existing license agreement with Arthrex as of the Effective Date was eliminated.
[9]	Pursuant to the Plan of Reorganization, all equity interests of the Company, including but not limited to all shares of the Company's common stock, $0.0001 par value per share (including its redeemable common stock) (the “Old Common Stock”), warrants and options, that were issuable or issued and outstanding immediately prior to the Effective Date, were cancelled. The elimination of the carrying value of the cancelled equity interests was reflected as direct charge to retained earnings (deficit).
[10]	Pursuant to the Plan of Reorganization, on the Effective Date, the Company issued 29,038 shares of Series A Preferred Stock to Deerfield. The Series A Preferred Stock has no stated maturity date, is not convertible or redeemable and carries a liquidation preference of $29,038,000, which is required to be paid to holders of such Series A Preferred Stock before any payments are made with respect to shares of New Common Stock (and other capital stock that is not issued on parity or senior to the Series A Preferred Stock) upon a liquidation or change in control transaction. The Series A Preferred Stock is carried at par value and is classified as equity.
[11]	Reflects the cumulative impact of the fresh start adjustments described above on additional paid in capital: Description Adjustment Amount Cash proceeds from issuance of common stock (1) $ 7,052,500 Establishment of intangible assets (2) 10,476,284 Net assets of the predecessor (5) 359,935 Less par value of common and preferred stock (3) (753 ) $ 17,887,966
[12]	Represents the cumulative impact of the reorganization adjustments: Description Adjustment Amount Elimination of existing intangible assets (a) $ (2,406,457) Elimination of prepaid Angel expenses (b) (16,053) Elimination of Angel deferred revenue (c) 899,920 Termination of debt agreements and accrued interest (d) 44,066,121 Elimination of various payables and accruals (e) 773,756 Cancellation of existing equity (f) 126,917,235 $170,234,522
[13]	Reflects the elimination of retained earnings upon the application of fresh start accounting.
[14]	Reflects the elimination of retained earnings upon the application of fresh start accounting.
[15]	Pursuant to the Plan of Reorganization, the Company assigned to Deerfield the Company's (i) rights, title and interest in and to its existing license agreement with Arthrex, (ii) the associated intellectual property owned by the Company and licensed under such agreement, and (iii) rights to collect royalty payments thereunder. As such, all deferred revenue related to the existing license agreement with Arthrex as of the Effective Date was eliminated.
[16]	Pursuant to the Plan of Reorganization, the Company's obligations under the Deerfield Facility Agreement including accrued interest were cancelled and the Company ceased to have any obligations thereunder. Additionally, pursuant to the Plan of Reorganization, the DIP Credit Agreement was terminated.
[17]	Represents claims not expected to be settled in cash.

Note 2 - Fresh Start Accounti36

Note 2 - Fresh Start Accounting - Cumulative Impact of the Reorganization Adjustments (Details)	May 05, 2016USD ($)
Elimination of existing intangible assets	$ (2,406,457)	[1],[2]
Elimination of prepaid Angel expenses	(16,053)	[3],[4]
Elimination of Angel deferred revenue	899,920	[5]
Termination of debt agreements and accrued interest	44,066,121	[6]
Elimination of various payables and accruals	773,756	[7]
Cancellation of existing equity	126,917,235	[8]
	$ 170,234,522	[9]
[1]	As a result of fresh start accounting, all intangible assets existing as of the Effective Date were established at fair value. This adjustment eliminates the carrying value of previously existing intangible assets as of the Effective Date as the underlying Angel assets were assigned to Deerfield pursuant to the Plan of Reorganization.
[2]	As a result of fresh start accounting, all intangible assets existing as of the Effective Date were established at fair value. This adjustment eliminates the carrying value of previously existing intangible assets as of the Effective Date as the underlying Angel assets were assigned to Deerfield pursuant to the Plan of Reorganization.
[3]	Pursuant to the Plan of Reorganization, the Company assigned to Deerfield the Company's (i) rights, title and interest in and to its existing license agreement with Arthrex, (ii) the associated intellectual property owned by the Company and licensed under such agreement, and (iii) rights to collect royalty payments thereunder. As such, certain prepaid expenses related to the Angel business were eliminated.
[4]	Pursuant to the Plan of Reorganization, the Company assigned to Deerfield the Company's (i) rights, title and interest in and to its existing license agreement with Arthrex, (ii) the associated intellectual property owned by the Company and licensed under such agreement, and (iii) rights to collect royalty payments thereunder. As such, certain prepaid expenses related to the Angel business were eliminated.
[5]	Pursuant to the Plan of Reorganization, the Company assigned to Deerfield the Company's (i) rights, title and interest in and to its existing license agreement with Arthrex, (ii) the associated intellectual property owned by the Company and licensed under such agreement, and (iii) rights to collect royalty payments thereunder. As such, all deferred revenue related to the existing license agreement with Arthrex as of the Effective Date was eliminated.
[6]	Pursuant to the Plan of Reorganization, the Company's obligations under the Deerfield Facility Agreement including accrued interest were cancelled and the Company ceased to have any obligations thereunder. Additionally, pursuant to the Plan of Reorganization, the DIP Credit Agreement was terminated.
[7]	Represents claims not expected to be settled in cash.
[8]	Pursuant to the Plan of Reorganization, all equity interests of the Company, including but not limited to all shares of the Company's common stock, $0.0001 par value per share (including its redeemable common stock) (the "Old Common Stock"), warrants and options, that were issuable or issued and outstanding immediately prior to the Effective Date, were cancelled. The elimination of the carrying value of the cancelled equity interests was reflected as direct charge to retained earnings (deficit).
[9]	Represents the cumulative impact of the reorganization adjustments: Description Adjustment Amount Elimination of existing intangible assets (a) $ (2,406,457) Elimination of prepaid Angel expenses (b) (16,053) Elimination of Angel deferred revenue (c) 899,920 Termination of debt agreements and accrued interest (d) 44,066,121 Elimination of various payables and accruals (e) 773,756 Cancellation of existing equity (f) 126,917,235 $170,234,522

Note 2 - Fresh Start Accounti37

Note 2 - Fresh Start Accounting - Reorganization Value of Fresh Start Adjustments (Details)	May 05, 2016USD ($)
Reorganization Value	$ 24,050,000
Estimated fair value of tangible assets	(13,574,000)
Estimated fair value of identifiable intangible assets	(8,397,000)
Goodwill	2,079,284
Revaluation of Assets [Member]
Reorganization Value	17,889,000
Revaluation of Liabilities [Member]
Reorganization Value	$ 6,161,000

Note 2 - Fresh Start Accounti38

Note 2 - Fresh Start Accounting - Cumulative Impact of Fresh Start Adjustments on APIC (Details)	May 05, 2016USD ($)
Cash proceeds from issuance of common stock	$ 7,052,500	[1],[2]
Establishment of intangible assets	10,476,284	[3]
Net assets of the predecessor	359,935	[4],[5]
Less par value of common and preferred stock	(753)	[6]
	$ 17,887,966	[7]
[1]	Pursuant to the Plan of Reorganization, as of the Effective Date, the Company issued 7,500,000 shares of New Common Stock, par value $0.0001 per share, to certain accredited investors for net cash to the Company of $7,052,500. The Company also issued Warrants to purchase 6,180,000 shares of New Common Stock to certain of the investors. The Warrants terminate on May 5, 2021 and are exercisable at any time on or after November 5, 2016 at exercise prices ranging from $0.50 per share to $1.00 per share. The number of shares of New Common Stock underlying a Warrant and its exercise price are subject to customary adjustments upon subdivisions, combinations, payment of stock dividends, reclassifications, reorganizations and consolidations. Certain investors also provided Backstop Commitments to purchase up to 12,800,000 additional shares of New Common Stock for an aggregate purchase price of up to $3,000,000. The Company cannot call the Backstop Commitment prior to June 30, 2017. The New Common Stock, Warrants and Backstop Commitment are classified as equity.
[2]	Pursuant to the Plan of Reorganization, as of the Effective Date, the Company issued 7,500,000 shares of new common stock, par value $0.0001 per share (the "New Common Stock"), to certain accredited investors for net cash to the Company of $7,052,500. The Company also issued warrants (the "Warrants") to purchase 6,180,000 shares of New Common Stock to certain of the investors. The Warrants terminate on May 5, 2021 and are exercisable at any time on or after November 5, 2016 at exercise prices ranging from $0.50 per share to $1.00 per share. The number of shares of New Common Stock underlying a Warrant and its exercise price are subject to customary adjustments upon subdivisions, combinations, payment of stock dividends, reclassifications, reorganizations and consolidations. Certain investors also provided backstop commitments (collectively, the "Backstop Commitment") to purchase up to 12,800,000 additional shares of New Common Stock for an aggregate purchase price of up to $3,000,000. The Company cannot call the Backstop Commitment prior to June 30, 2017. The New Common Stock, Warrants and Backstop Commitment are classified as equity.
[3]	(2) Represents identifiable intangible assets of approximately $8.4 million and goodwill of approximately $2.1 million. Upon the application of fresh start accounting, the Company allocated the reorganization value to its individual assets based on their estimated fair values. Reorganization value represents the fair value of the Successor Company's assets before considering liabilities, and the excess of reorganization value over the fair value of identified tangible and intangible assets is reported separately on the consolidated balance sheet as goodwill. The Company, with the assistance of external valuation specialists, estimated the enterprise value of the Company upon emergence from Chapter 11 bankruptcy to be $17.9 million. Enterprise value is defined as the total invested capital, which includes cash and cash equivalents. The estimate is based on a calculation of the present value of the projected future cash flows of the Company from May 5, 2016 through the year ending December 31, 2025 along with a terminal value. The Company estimated a terminal value using the Gordon Growth Model. In applying fresh start accounting, the Company followed these principles: ? The reorganization value, estimated as approximately $24.0 million, which represents the sum of the enterprise value and estimated fair value of noninterest bearing liabilities, was allocated to the Successor Company's assets based on their estimated fair values. The reorganization value exceeded the sum of the fair value assigned to the assets, and the excess was recognized as goodwill of the Successor Company as of May 5, 2016. ? Each liability existing as of May 5, 2016 has been stated at its estimated fair value. ? Deferred tax assets and liabilities have been recognized for differences between the assigned values and the tax basis of the recognized assets and liabilities, and have been fully valued as of May 5, 2016 to reduce deferred tax assets to the amounts expected to be realized. Pursuant to fresh start accounting the Company allocated the determined reorganization value to the Successor Company’s assets as follows (in thousands): Enterprise Value $ 17,889 Plus estimated fair value of liabilities 6,161 Reorganization Value 24,050 Less: Estimated fair value of tangible assets (13,574 ) Estimated fair value of identifiable intangible assets (8,397 ) Goodwill $ 2,079
[4]	Reflects the elimination of retained earnings upon the application of fresh start accounting.
[5]	Reflects the elimination of retained earnings upon the application of fresh start accounting.
[6]	Pursuant to the Plan of Reorganization, on the Effective Date, the Company issued 29,038 shares of Series A Preferred Stock to Deerfield. The Series A Preferred Stock has no stated maturity date, is not convertible or redeemable and carries a liquidation preference of $29,038,000, which is required to be paid to holders of such Series A Preferred Stock before any payments are made with respect to shares of New Common Stock (and other capital stock that is not issued on parity or senior to the Series A Preferred Stock) upon a liquidation or change in control transaction. The Series A Preferred Stock is carried at par value and is classified as equity.
[7]	Reflects the cumulative impact of the fresh start adjustments described above on additional paid in capital: Description Adjustment Amount Cash proceeds from issuance of common stock (1) $ 7,052,500 Establishment of intangible assets (2) 10,476,284 Net assets of the predecessor (5) 359,935 Less par value of common and preferred stock (3) (753 ) $ 17,887,966

Note 2 - Fresh Start Accounti39

Note 2 - Fresh Start Accounting - Summary of Reorganization Items, Net (Details) - USD ($)	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2015
Professional fees		$ 324,551
Net gain on reorganization adjustments
Reorganization items, net		324,551
Cash payments for reorganization items		$ 1,507,863
Predecessor [Member]
Professional fees	$ 3,598,216
Net gain on reorganization adjustments	(34,869,566)
Reorganization items, net	(31,271,350)
Cash payments for reorganization items	$ 1,839,560

Note 3 - Liquidity and Summar40

Note 3 - Liquidity and Summary of Significant Accounting Policies (Details Textual)	Dec. 04, 2015	Aug. 11, 2015	Jan. 31, 2016USD ($)	Sep. 30, 2015USD ($)	Mar. 31, 2015USD ($)	May 04, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Cash and Cash Equivalents, at Carrying Value						$ 10,358,209	$ 2,620,023	$ 2,620,023
Backstop Commitments							3,000,000	3,000,000
Cash, Uninsured Amount							2,400,000	2,400,000
Cash, FDIC Insured Amount							250,000	250,000
Allowance for Doubtful Accounts Receivable							409,000	409,000	$ 97,000
Inventory, Finished Goods, Net of Reserves							18,123	18,123	115,792
Inventory, Raw Materials, Net of Reserves							59,798	59,798	196,500
Inventory Valuation Reserves							$ 8,000	8,000	58,000
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)								0
Goodwill, Impairment Loss				$ 1,100,000				$ 0
Number of Reporting Units								1
License and Maintenance Revenue						$ 140,000			$ 400,000
License and Services Revenue					$ 3,000,000
Percentage of Product Sales						11.00%	22.00%		31.00%
Number of Operating Segments								1
Remaining Accrual for Business Exit Costs							$ 200,000	$ 200,000	$ 200,000
Restructuring Reserve, Current							0	0	300,000
Debt, Long-term and Short-term, Combined Amount							$ 0	0
Impairment of Intangible Assets (Excluding Goodwill)								$ 0
The 2016 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares								1,370
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares								0
Employee Stock Option [Member]
Fair Value Assumptions, Expected Dividend Rate								0.00%
Realignment Plan [Member]
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent	22.00%	30.00%
Restructuring and Related Cost, Expected Number of Positions Eliminated	7		4
Severance Costs			$ 500,000						900,000
Realignment Plan [Member] | Selling and Marketing Expense [Member]
Severance Costs									200,000
Realignment Plan [Member] | Research and Development Expense [Member]
Severance Costs									200,000
Realignment Plan [Member] | General and Administrative Expense [Member]
Severance Costs									400,000
Product Revenues [Member]
Deferred Revenue									100,000
Licensing Agreements [Member]
Deferred Revenue									1,000,000
Predecessor [Member]
Cash and Cash Equivalents, at Carrying Value						$ 10,358,209			922,317	$ 15,946,425
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)				22,600,000
Goodwill, Impairment Loss				1,100,000					$ 1,128,517
Goodwill, Fair Value Disclosure				$ 0
Minimum [Member]
Inventory Shelf Life									1 year 180 days
Minimum [Member] | Property and Equipment Excluding Furniture, Lab, and Manufacturing Equipment [Member]
Property, Plant and Equipment, Useful Life								1 year
Minimum [Member] | Furniture, Lab and Manufacturing Equipment [Member]
Property, Plant and Equipment, Useful Life								4 years
Minimum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life								3 years
Maximum [Member]
Inventory Shelf Life									2 years
Maximum [Member] | Property and Equipment Excluding Furniture, Lab, and Manufacturing Equipment [Member]
Property, Plant and Equipment, Useful Life								4 years
Maximum [Member] | Furniture, Lab and Manufacturing Equipment [Member]
Property, Plant and Equipment, Useful Life								6 years
Maximum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life								6 years

Note 3 - Liquidity and Summar41

Note 3 - Liquidity and Summary of Significant Accounting Principles - Summary of Concentration Risk (Details) - Customer Concentration Risk [Member]	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2015
Sales Revenue, Net [Member] | Customer B [Member]
Concentration percentage
Sales Revenue, Net [Member] | Customer B [Member] | Predecessor [Member]
Concentration percentage	78.00%		67.00%
Sales Revenue, Net [Member] | Customer C [Member]
Concentration percentage
Sales Revenue, Net [Member] | Customer C [Member] | Predecessor [Member]
Concentration percentage			26.00%
Sales Revenue, Net [Member] | Customer D [Member]
Concentration percentage		22.00%
Sales Revenue, Net [Member] | Customer D [Member] | Predecessor [Member]
Concentration percentage
Sales Revenue, Net [Member] | Customer E [Member]
Concentration percentage		16.00%
Sales Revenue, Net [Member] | Customer E [Member] | Predecessor [Member]
Concentration percentage
Accounts Receivable [Member] | Customer B [Member]
Concentration percentage	10.00%
Accounts Receivable [Member] | Customer B [Member] | Predecessor [Member]
Concentration percentage			21.00%
Accounts Receivable [Member] | Customer A [Member]
Concentration percentage	58.00%
Accounts Receivable [Member] | Customer A [Member] | Predecessor [Member]
Concentration percentage			47.00%

Note 3 - Liquidity and Summar42

Note 3 - Liquidity and Summary of Significant Accounting Policies - Summary Stock Option Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Risk free rate, minimum	1.80%	1.40%
Risk free rate, maximum	2.00%	1.70%
Weighted average expected years until exercise (Year)		6 years 109 days
Expected stock volatility	83.00%
Expected stock volatility, minimum		93.00%
Expected stock volatility, maximum		117.00%
Minimum [Member]
Weighted average expected years until exercise (Year)	4 years 292 days
Maximum [Member]
Weighted average expected years until exercise (Year)	6 years

Note 3 - Liquidity and Summar43

Note 3 - Liquidity and Summary of Significant Accounting Policies - Anti-dilutive Securities Excluded From the Computation of Diluted Earnings (Loss) Per Share (Details) - shares	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2015
Employee Stock Option [Member]
Anti-dilutive Securities (in shares)		1,265,000
Employee Stock Option [Member] | Predecessor [Member]
Anti-dilutive Securities (in shares)	9,173,119		11,069,166
Warrant [Member]
Anti-dilutive Securities (in shares)		6,180,000
Warrant [Member] | Predecessor [Member]
Anti-dilutive Securities (in shares)	113,629,178		116,034,682
Convertible Debt Securities [Member]
Anti-dilutive Securities (in shares)
Convertible Debt Securities [Member] | Predecessor [Member]
Anti-dilutive Securities (in shares)			73,342,730

Note 3 - Liquidity and Summar44

Note 3 - Liquidity and Summary of Significant Accounting Policies - Earnings (Loss) Per Share (Details) - USD ($)	4 Months Ended	8 Months Ended		12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Net income (loss)		$ (5,695,627)	$ (5,695,627)
Numerator adjustment for potential dilutive securities		0
Numerator for diluted income (loss) per share		$ (5,695,027)
Basic (in shares)		9,895,966
Dilutive effect of convertible debt (in shares)		0
Denominator for diluted income (loss) per share weighted average outstanding common shares (in shares)		9,895,966
Basic and diluted earnings (loss) per share
Basic (in dollars per share)		$ (0.58)
Diluted (in dollars per share)		$ (0.58)
Predecessor [Member]
Net income (loss)	$ 28,173,934			$ (52,808,108)
Numerator adjustment for potential dilutive securities	172,546			0
Numerator for diluted income (loss) per share	$ 28,346,480			$ (52,808,108)
Basic (in shares)	125,951,100			125,951,100
Dilutive effect of convertible debt (in shares)	67,307,692			0
Denominator for diluted income (loss) per share weighted average outstanding common shares (in shares)	193,258,792			125,951,100
Basic and diluted earnings (loss) per share
Basic (in dollars per share)	$ 0.22			$ (0.42)
Diluted (in dollars per share)	$ 0.15			$ (0.42)

Note 4 - Distribution, Licens45

Note 4 - Distribution, Licensing and Collaboration Arrangements (Details Textual)	Oct. 31, 2016USD ($)	Oct. 28, 2016USD ($)	Oct. 20, 2016USD ($)	May 05, 2016USD ($)$ / item	Mar. 22, 2016USD ($)	Dec. 31, 2016USD ($)	Nov. 30, 2016USD ($)	Jan. 31, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2016	Dec. 31, 2013USD ($)
Other Income									$ 50,000
Repayments of Related Party Debt		$ 201,200
Debt Instrument, Number of Periodic Payments			3
Debt Instrument, Periodic Payment			$ 33,333
Distribution Agreement with Boyalife [Member] | Affiliated Entity [Member]
License Agreement, Original Term				5 years
Due from Related Parties, Current				$ 500,000
Maximum Payment on Right Excercisable				$ 250,000
Distribution Agreement with Boyalife [Member] | Affiliated Entity [Member] | Aurix System [Member]
Distribution Fee per Unit Sold | $ / item				40
Restorix Distribution Agreement [Member]
Collaboration Agreement, Term					2 years
Restorix Distribution Agreement [Member] | Minimum [Member]
Collaboration Agreement, Available Extension of Term					1
Current Product Price					$ 700
Restorix Distribution Agreement [Member] | Maximum [Member]
Current Product Price					$ 750
Arthrex and Deerfield SS, LLC [Member]
Proceeds from License Fees Received	$ 33,333					$ 33,333	$ 33,333
Arthrex [Member]
Debt Instrument, Increase (Decrease), Net				$ 15,000,000
Rohto Pharmaceutical Co., Ltd [Member]
Proceeds from License Fees Received								$ 3,000,000
Millennia Holdings, Inc [Member]
Payments for Terminated Licenses								$ 1,500,000
Distributor and License Agreement with Arthrex [Member]
License Agreement, Original Term										5 years	5 years
License Agreement, Additional Term											3 years
License Agreement, Minimum Required Period from End of Original Term to Terminate Term Extension											1 year
Advance Royalties											$ 5,000,000

Note 5 - Receivables - Accounts

Note 5 - Receivables - Accounts and Other Receivable, Net (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accounts receivable, gross	$ 703,675
Less allowance for doubtful accounts	(409,377)
	294,298
Predecessor [Member]
Accounts receivable, gross		$ 1,110,993
Less allowance for doubtful accounts		(96,748)
		1,014,245
Trade Accounts Receivable [Member]
Accounts receivable, gross	100,660
Trade Accounts Receivable [Member] | Predecessor [Member]
Accounts receivable, gross		460,763
Other Receivables [Member]
Accounts receivable, gross	$ 603,015
Other Receivables [Member] | Predecessor [Member]
Accounts receivable, gross		$ 650,230

Note 6 - Property and Equipme47

Note 6 - Property and Equipment (Details Textual) - USD ($)	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2015
Depreciation, Depletion and Amortization, Nonproduction	$ 249,000	$ 280,000	$ 433,000
General and Administrative Expense [Member]
Depreciation, Depletion and Amortization, Nonproduction	80,000	100,000	246,000
Selling and Marketing Expense [Member]
Depreciation, Depletion and Amortization, Nonproduction	9,000	12,000	25,000
Research and Development Expense [Member]
Depreciation, Depletion and Amortization, Nonproduction	37,000	70,000	68,000
Reorganization Items, Net [Member]
Depreciation, Depletion and Amortization, Nonproduction	67,000
Cost of Sales [Member]
Depreciation, Depletion and Amortization, Nonproduction	$ 56,000	$ 98,000	$ 94,000

Note 6 - Property and Equipme48

Note 6 - Property and Equipment - Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, plant, and equipment, gross	$ 765,717	$ 2,201,846
Less accumulated depreciation and amortization	(279,601)	(1,086,632)
	486,116	1,115,214
Medical Equipment [Member]
Property, plant, and equipment, gross	405,096	1,195,467
Office Equipment [Member]
Property, plant, and equipment, gross	48,888	142,827
Technology Equipment [Member]
Property, plant, and equipment, gross	257,619	523,571
Manufacturing Equipment [Member]
Property, plant, and equipment, gross	34,899	307,851
Leasehold Improvements [Member]
Property, plant, and equipment, gross	$ 19,215	$ 32,130

Note 7 - Goodwill and Other I49

Note 7 - Goodwill and Other Intangible Assets (Details Textual) - USD ($)	1 Months Ended		3 Months Ended	4 Months Ended	8 Months Ended	12 Months Ended
	Feb. 29, 2012	Apr. 30, 2010	Sep. 30, 2015	May 04, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	May 05, 2016	Dec. 31, 2014
Goodwill, Impairment Loss			$ 1,100,000			$ 0
Goodwill			0		$ 2,079,284	$ 2,079,284	0	$ 2,100,000	$ 0
Amortization of Intangible Assets					600,000
Angel [Member]
Amortization of Intangible Assets				$ 100,000			200,000
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life						9 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life						15 years
Predecessor [Member]
Goodwill, Impairment Loss			$ 1,100,000				1,128,517
Goodwill									$ 1,128,517
Predecessor [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life						8 years
Predecessor [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life						20 years
Aldagen [Member]
Goodwill, Acquired During Period	$ 400,000
Angel [Member]
Goodwill, Acquired During Period		$ 700,000

Note 7 - Goodwill and Other I50

Note 7 - Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($)	Dec. 31, 2016	May 05, 2016	Dec. 31, 2015
Finite-lived intangible assets, gross	$ 8,397,000
Accumulated amortization	(556,592)
	7,840,408	$ 8,400,000
Predecessor [Member]
Finite-lived intangible assets, gross			$ 4,110,000
Accumulated amortization			(1,596,606)
			2,513,394
Trademarks [Member]
Finite-lived intangible assets, gross	917,000
Accumulated amortization	(39,934)
Trademarks [Member] | Predecessor [Member]
Finite-lived intangible assets, gross			1,047,000
Accumulated amortization			(184,981)
Technology-Based Intangible Assets [Member]
Finite-lived intangible assets, gross	6,576,000
Accumulated amortization	(477,290)
Technology-Based Intangible Assets [Member] | Predecessor [Member]
Finite-lived intangible assets, gross			2,355,000
Accumulated amortization			(902,750)
Customer Relationships [Member]
Finite-lived intangible assets, gross	904,000
Accumulated amortization	$ (39,368)
Customer Relationships [Member] | Predecessor [Member]
Finite-lived intangible assets, gross			708,000
Accumulated amortization			$ (508,875)

Note 7 - Goodwill and Other I51

Note 7 - Goodwill and Other Intangible Assets - Changes in Goodwill (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	May 05, 2016	[1]
Balance		$ 0	$ 0
2015 impairment	$ (1,100,000)	0
Balance	0	2,079,284	0
Fresh start accounting		2,079,284		$ 2,079,284
Predecessor [Member]
Balance			1,128,517
2015 impairment	$ (1,100,000)		(1,128,517)
Balance
Fresh start accounting
[1]	Represents identifiable intangible assets of approximately $8.4 million and goodwill of approximately $2.1 million. Upon the application of fresh start accounting, the Company allocated the reorganization value to its individual assets based on their estimated fair values. Reorganization value represents the fair value of the Successor Company’s assets before considering liabilities, and the excess of reorganization value over the fair value of identified tangible and intangible assets is reported separately on the consolidated balance sheet as goodwill. The Company, with the assistance of external valuation specialists, estimated the enterprise value of the Company upon emergence from Chapter 11 bankruptcy to be $17.9 million. Enterprise value is defined as the total invested capital, which includes cash and cash equivalents. The estimate is based on a calculation of the present value of the projected future cash flows of the Company from May 5, 2016 through the year ending December 31, 2025 along with a terminal value. The Company estimated a terminal value using the Gordon Growth Model. In applying fresh start accounting, the Company followed these principles: ? The reorganization value, estimated as approximately $24.0 million, which represents the sum of the enterprise value and estimated fair value of noninterest bearing liabilities, was allocated to the Successor Company's assets based on their estimated fair values. The reorganization value exceeded the sum of the fair value assigned to the assets, and the excess was recognized as goodwill of the Successor Company as of May 5, 2016. ? Each liability existing as of May 5, 2016 has been stated at its estimated fair value. ? Deferred tax assets and liabilities have been recognized for differences between the assigned values and the tax basis of the recognized assets and liabilities, and have been fully valued as of May 5, 2016 to reduce deferred tax assets to the amounts expected to be realized. Pursuant to fresh start accounting the Company allocated the determined reorganization value to the Successor Company's assets as follows (in thousands): Enterprise Value $ 17,889 Plus estimated fair value of liabilities 6,161 Reorganization Value 24,050 Less: Estimated fair value of tangible assets (13,574 ) Estimated fair value of identifiable intangible assets (8,397 ) Goodwill $ 2,079

Note 7 - Goodwill and Other I52

Note 7 - Goodwill and Other Intangible Assets - Annual Amortization Expense (Details)	Dec. 31, 2016USD ($)
2,017	$ 852,000
2,018	852,000
2,019	852,000
2,020	852,000
2,021	852,000
Thereafter	$ 3,580,000

Note 8 - Accrued Liabilities (D

Note 8 - Accrued Liabilities (Details Textual) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accrued Machine Refurbishment and Design Improvement Costs	$ 465,000	$ 465,000	$ 600,000

Note 8 - Accrued Liabilities -

Note 8 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Customer deposits	$ 72,192	$ 611,341
Accrued compensation and benefits	91,325	532,435
Other payables	124,484	518,734
Due to Arthrex		31,785
Accrued professional fees	213,116	190,787
Accrued loss on abandonment of lease, current portion	88,560	103,173
Accrued Angel machine rework costs	465,000	465,000	$ 600,000
	$ 1,054,677	$ 2,453,255

Note 9 - Deferred Revenue (Deta

Note 9 - Deferred Revenue (Details Textual) - USD ($)		4 Months Ended	8 Months Ended	12 Months Ended
		May 04, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2013	May 05, 2016
Licenses Revenue
Reorganization Adjustment, Increase (Decrease), Deferred Revenue, Current Portion	[1]						$ (899,920)
Distributor and License Agreement with Arthrex [Member]
License Agreement, Original Term				5 years		5 years
Licenses Revenue		$ 140,000			$ 402,000
Reorganization Adjustment, Increase (Decrease), Deferred Revenue, Current Portion		$ (900,000)
[1]	Pursuant to the Plan of Reorganization, the Company assigned to Deerfield the Company's (i) rights, title and interest in and to its existing license agreement with Arthrex, (ii) the associated intellectual property owned by the Company and licensed under such agreement, and (iii) rights to collect royalty payments thereunder. As such, all deferred revenue related to the existing license agreement with Arthrex as of the Effective Date was eliminated.

Note 10 - Debt (Details Textual

Note 10 - Debt (Details Textual) - USD ($)	May 05, 2016	Jan. 28, 2016	May 04, 2016	Dec. 31, 2016	Dec. 31, 2014	Mar. 09, 2016	Jan. 26, 2016	Dec. 31, 2015	Dec. 18, 2015	Dec. 17, 2015	Oct. 01, 2015
Debt Instrument, Unamortized Discount					$ 34,800,000
Interest Payable, Current
Debt, Long-term and Short-term, Combined Amount				$ 0
Predecessor [Member]
Interest Payable, Current								$ 3,143,470
Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues	29,038
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	6,180,000
Stock Issued During Period, Shares, Other	200,000				2,709,677
Debt Issuance Costs, Line of Credit Arrangements, Net					$ 1,100,000
Stock Issued During Period, Shares, New Issues	7,500,000			2,264,612
Deerfield Facility Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 35,000,000
Debt Instrument, Term					5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.52
Debt Instrument, Redemption Price, Percentage					33.33%
Equity Raising Transaction, Proceeds, Percentage Applied for Redemption					35.00%
Put Options, Amount Exempt					$ 10,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					97,614,999
Debt Instrument, Covenant, Minimum Cash Balance									$ 500,000	$ 5,000,000	$ 5,000,000
Interest Payable, Current											$ 2,600,000
Debt, Current							$ 38,300,000
Deerfield Facility Agreement [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues	29,038
DIP Credit Agreement [Member]
Debt, Current							$ 5,750,000
DIP Loans [Member]
Proceeds from Issuance of Debt			$ 5,750,000
Debt Instrument, Fee Amount			$ 300,000
DIP Loans [Member] | Predecessor [Member]
Line of Credit Facility, Maximum Borrowing Capacity						$ 6,000,000
Percentage of Lenders of Existing Debt		100.00%

Note 11 - Equity and Stock-ba57

Note 11 - Equity and Stock-based Compensation (Details Textual)	Jun. 20, 2016USD ($)shares	May 05, 2016USD ($)$ / sharesshares	Mar. 31, 2014USD ($)$ / sharesshares	May 04, 2016USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Aug. 04, 2016shares	Jun. 09, 2014shares
Authorized Shares, Common and Preferred					32,500,000	32,500,000
Common Stock, Shares Authorized					31,500,000	31,500,000	425,000,000
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized					1,000,000	1,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares					$ 0.0001	$ 0.0001
Payment for Offering Cost | $		$ 100,000
Warrant, Expiration Date		May 5, 2021
Class of Warrant or Right, Date from which Warrants or Rights Exercisable		Nov. 5, 2016
Preferred Stock, Liquidation Preference, Value | $					$ 29,038,000	$ 29,038,000
Warrants Issued for Services [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $							$ 0
Class of Warrant or Right, Issued During Period						0
Class of Warrant or Right, Exercised During Period						0
Long Term Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									10,500,000
Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									18,000,000
Long Term Incentive and Equity Incentive Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				0		0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				0			1,033,259
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $							$ 810,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							2 years 219 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares							$ 0.18
Long Term Incentive and Equity Incentive Plans [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $				$ 300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				2 years 146 days
Stock Granted, Value, Share-based Compensation, Gross | $							$ 187,000
The 2016 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					1,500,000	1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					1,370,000	1,370,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $					$ 140,000	$ 140,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition						1 year 146 days
Stock Granted, Value, Share-based Compensation, Gross | $						$ 233,000
Class of Warrant or Right, Issued During Period						0
Evergreen Provision, Increase in Number of Shares Authorized Calculation, Percentage Amount of Prior Year's Reserved Shares								6.00%
Evergreen Provision, Maximum Limit of Increase to Authorized Shares								1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $						$ 56,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues			3,846,154
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.52
Proceeds from Issuance of Private Placement | $			$ 2,000,000
Derivative Liability | $			1,100,000
Payments of Stock Issuance Costs | $			$ 136,000
Predecessor [Member]
Authorized Shares, Common and Preferred							440,000,000
Common Stock, Shares Authorized							425,000,000
Common Stock, Voting Rights Per Share							1
Common Stock, Dividends, Per Share, Cash Paid | $ / shares						$ 0	$ 0
Common Stock, Dividends, Per Share, Declared | $ / shares						$ 0	$ 0
Series A Preferred Stock [Member]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.0001
Preferred Stock, Shares Authorized		29,038
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 0.0001
Stock Issued During Period, Shares, New Issues		29,038
Preferred Stock, Liquidation Preference, Value | $		$ 29,038,000
Number of Board Members Nominated and Elected by Shareholders		1
Preferred Stock, Voting Rights, Number of Votes Per Share		5
Preferred Stock, Voting Rights, Percentage of Voting Rights of Capital Stock		1.00%
Preferred Stock, Restrictions, Debt Ceiling Other Than for Working Capital Purposes | $		$ 3,000,000
Convertible Preferred Stock [Member] | Predecessor [Member]
Preferred Stock, Shares Authorized							15,000,000
Common Stock [Member]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.0001
Stock Issued During Period, Shares, New Issues		7,500,000			2,264,612
Proceeds from Issuance of Common Stock | $		$ 7,300,000
Proceeds from Issuance of Common Stock, Net of Issuance Costs | $		7,052,500
Payment for Offering Cost | $		$ 100,000
Backstop Commitment Date		Jun. 30, 2017
Commitment Fees for Debt | $		$ 250,000
Stock Issued During Period, Shares, Issued for Services					162,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		6,180,000
Warrant, Expiration Date		May 5, 2021
Class of Warrant or Right, Date from which Warrants or Rights Exercisable		Nov. 5, 2016
Common Stock [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.50
Common Stock [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 1
Common Stock [Member] | Backstop Commitment [Member]
Number of Shares Commited to Purchase		12,800,000
Value of Shares Commited to Purchase | $		$ 3,000,000
Exchange Shares [Member]
Stock Issued During Period, Shares, New Issues		2,264,612
Number of Shares Commited to Issue		3,000,000
Shares of Old Common Stock to New Common Stock, Conversion Ratio		41.8934
Administrative Claim Shares [Member]
Stock Issued During Period, Shares, New Issues	162,500
Stock Issued During Period, Shares, Issued for Services	100,000
Debt Conversion, Converted Instrument, Shares Issued	62,500
Debt Conversion, Original Debt, Amount | $	$ 62,500
March 2014 Warrant [Member] | Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,884,615
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.52
Warrant, Term			5 years

Note 11 - Equity and Stock-ba58

Note 11 - Equity and Stock-based Compensation - Warrants Outstanding (Details)	May 04, 2016$ / sharesshares
Outstanding (in shares)	113,629,178
Stock Purchase Warrants 1 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.40
Expiration Date	2016-06
Outstanding (in shares)	20,000
Stock Purchase Warrants 2 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.66
Expiration Date	2018-02
Outstanding (in shares)	136,364
Stock Purchase Warrants 3 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.75
Expiration Date	2018-02
Outstanding (in shares)	6,363,638
Stock Purchase Warrants 4 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.65
Expiration Date	2017-12
Outstanding (in shares)	5,047,461
Stock Purchase Warrants 5 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.65
Expiration Date	2017-12
Outstanding (in shares)	232,964
Stock Purchase Warrants 6 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.52
Expiration Date	2019-03
Outstanding (in shares)	2,884,615
Stock Purchase Warrants 7 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.52
Expiration Date	2019-03
Outstanding (in shares)	1,474,615
Stock Purchase Warrants 8 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.52
Expiration Date	2019-06
Outstanding (in shares)	3,525,000
Stock Purchase Warrants 9 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.70
Expiration Date	2020-02
Outstanding (in shares)	1,079,137
Stock Purchase Warrants 10 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.70
Expiration Date	2020-02
Outstanding (in shares)	250,000
Stock Purchase Warrants 11 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.52
Expiration Date	2021-03
Outstanding (in shares)	25,115,384
Stock Purchase Warrants 12 [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.52
Expiration Date	2021-06
Outstanding (in shares)	67,500,000

Note 11 - Equity and Share-base

Note 11 - Equity and Share-based Compensation - Stock Options, Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	May 05, 2016
Shares outstanding, weighted-average remaining contractual term (Year)			9 years 186 days
Shares outstanding (in shares)		1,265,000	1,265,000
Shares outstanding, weighted-average exercise price (in dollars per share)		$ 1	$ 1
Shares exercisable (in shares)		331,665	331,665
Shares exercisable, weighted-average exercise price (in dollars per share)		$ 1	$ 1
Long Term Incentive and Equity Incentive Plans [Member]
Shares outstanding (in shares)	11,069,166		11,069,166
Shares outstanding, weighted-average exercise price (in dollars per share)	$ 0.78		$ 0.78
Shares outstanding, weighted-average remaining contractual term (Year)				6 years 36 days
Shares outstanding, aggregate intrinsic value
Shares granted (in shares)	0			1,033,259
Shares granted, weighted-average exercise price (in dollars per share)
Shares exercised (in shares)	0		0	0
Shares exercised, weighted-average exercise price (in dollars per share)
Shares forfeited or expired (in shares)	(11,069,166)
Shares forfeited or expired, weighted-average exercise price (in dollars per share)	$ 0.78
Shares outstanding (in shares)				11,069,166
Shares outstanding, weighted-average exercise price (in dollars per share)				$ 0.78
Shares exercisable (in shares)
Shares exercisable, weighted-average exercise price (in dollars per share)
Shares exercisable, weighted-average remaining contractual term (Year)
Shares vested & expected to vest (in shares)
Shares vested & expected to vest, weighted-average exercise price (in dollars per share)
Shares vested & expected to vest, weighted-average remaining contractual term (Year)
The 2016 Omnibus Plan [Member]
Shares outstanding, weighted-average remaining contractual term (Year)	0 years	9 years 186 days
Shares outstanding, aggregate intrinsic value		$ 0	$ 0		$ 0
Shares granted (in shares)		1,370,000	1,370,000
Shares granted, weighted-average exercise price (in dollars per share)		$ 1
Shares exercised (in shares)			0
Shares exercised, weighted-average exercise price (in dollars per share)
Shares forfeited or expired (in shares)		(105,000)
Shares forfeited or expired, weighted-average exercise price (in dollars per share)
Shares outstanding (in shares)	0	1,265,000	1,265,000
Shares outstanding, weighted-average exercise price (in dollars per share)	$ 0	$ 1	$ 1
Shares exercisable (in shares)		331,665	331,665
Shares exercisable, weighted-average exercise price (in dollars per share)		$ 1	$ 1
Shares exercisable, weighted-average remaining contractual term (Year)		9 years 186 days
Shares vested & expected to vest (in shares)		1,265,000	1,265,000
Shares vested & expected to vest, weighted-average exercise price (in dollars per share)		$ 1	$ 1
Shares vested & expected to vest, weighted-average remaining contractual term (Year)		9 years 186 days
Shares granted, weighted-average remaining contractual term (Year)		10 years

Note 11 - Equity and Stock-ba60

Note 11 - Equity and Stock-based Compensation - Warrants to Service Providers, Activity (Details) - Warrants Issued for Services [Member] - $ / shares	4 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2015
Outstanding (in shares)	406,364
Outstanding, weighted-average exercise price (in dollars per share)	$ 0.67
Outstanding, weighted-average remaining contractual term (Year)		3 years 109 days
Granted (in shares)
Exercised (in shares)
Forfeited or expired (in shares)	(406,364)
Forfeited or expired, weighted-average exercise price (in dollars per share)	$ 0.67
Outstanding (in shares)		406,364
Outstanding, weighted-average exercise price (in dollars per share)		$ 0.67
Exercisable (in shares)
Exercisable, weighted-average exercise price (in dollars per share)
Exercisable, weighted-average remaining contractual term (Year)

Note 11 - Equity and Stock-ba61

Note 11 - Equity and Stock-based Compensation - Stock Options, Exercise Price Ranges (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Exercise price (in dollars per share)	$ 1
Options outstanding, number of shares (in shares) | shares	1,265,000
Shares outstanding, weighted-average remaining contractual term (Year)	9 years 186 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 1
Shares exercisable (in shares) | shares	331,665
Shares exercisable, weighted-average exercise price (in dollars per share)	$ 1

Note 11 - Equity and Stock-ba62

Note 11 - Equity and Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2015
Share-based compensation		$ 74,999
Predecessor [Member]
Share-based compensation	$ 55,081		$ 782,755
Selling and Marketing Expense [Member]
Share-based compensation		8,963
Selling and Marketing Expense [Member] | Predecessor [Member]
Share-based compensation	18,504		156,297
Research and Development Expense [Member]
Share-based compensation		9,769
Research and Development Expense [Member] | Predecessor [Member]
Share-based compensation	6,858		74,989
General and Administrative Expense [Member]
Share-based compensation		$ 56,267
General and Administrative Expense [Member] | Predecessor [Member]
Share-based compensation	$ 29,719		$ 551,469

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) $ in Thousands	Dec. 31, 2016USD ($)
Operating Loss Carryforwards	$ 163,200
Liability for Uncertainty in Income Taxes, Current	$ 0

Note 12 - Income Taxes - Income

Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal		$ 0
State		0
Deferred:
Federal		1,989,763
State		236,490
Change in valuation allowance		2,226,253
Total Benefit for Income Taxes
Predecessor [Member]
Current:
Federal	$ 0
State	0
Deferred:
Federal	(9,836,756)		29,084,623
State	(2,237,382)		3,614,773
Change in valuation allowance	(12,074,138)		32,610,383
Total Benefit for Income Taxes			$ 89,013

Note 12 - Income Taxes - Deferr

Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2016	May 04, 2016
Deferred tax assets:
Stock-based compensation	$ 29,379	$ 6,238,000
Tax credits	3,484,799	3,339,000
Deferred revenue		462,000
Start-up and organizational costs	270,652	275,000
Tax deductible Goodwill	354,831	404,000
Property and equipment	163,755	207,000
Other	224,910	283,000
Total deferred tax assets	4,528,326	11,208,000
Deferred tax liabilities:
Intangible Assets	(2,374,950)	(114,000)
Total deferred tax liabilities	(2,374,950)	(114,000)
Net deferred tax assets, excluding net operating loss carryforwards	2,153,376	11,094,000
Net operating loss carryforwards	50,713,527	61,076,000
Deferred tax assets, gross, noncurrent	52,866,903	72,170,000
Less valuation allowance	(52,866,903)	(72,170,000)
Total deferred tax assets (liabilities)

Note 12 - Income Taxes - Inco66

Note 12 - Income Taxes - Income Tax Rate Reconciliation (Details)	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2016	Dec. 31, 2015
U.S. federal statutory income tax	35.00%	35.00%	35.00%
State and local income tax, net of benefits	4.20%	4.20%	4.80%
Fair value of derivatives			22.40%
Other	3.70%	(0.10%)	(0.40%)
Valuation allowance for deferred income tax assets	(42.90%)	(39.10%)	(61.60%)
Effective income tax rate			0.20%

Note 13 - Fair Value Measurem67

Note 13 - Fair Value Measurements (Details Textual) - USD ($)	Oct. 24, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Feb. 28, 2014
Convertible Debt, Fair Value Disclosures					$ 25,400,000
Time Deposits, at Carrying Value						$ 53,000
Time Deposits, Annual Interest Rate						0.10%
Time Deposits, Interest Rate, Renewal Term	240 days
Asset Impairment Charges			$ 0
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)				$ 0
Goodwill, Impairment Loss		$ 1,100,000		$ 0
In Process Research and Development, Indefinite-Lived [Member]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		$ 22,600,000

Note 13 - Fair Value Measurem68

Note 13 - Fair Value Measurements - Fair Value of Intangible Assets (Details)	Dec. 31, 2016USD ($)
Trademarks [Member] | Income Approach, Royalty Savings Method [Member]
Fair value of intangible assets	$ 917,000
Technology [Member] | Income Approach, Royalty Savings Method [Member]
Fair value of intangible assets	6,576,000
Clinician Relationships [Member] | Income Approach, Excess Earnings Method [Member]
Fair value of intangible assets	$ 904,000

Note 13 - Fair Value Measurem69

Note 13 - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - Fair Value, Measurements, Recurring [Member]	Dec. 31, 2015USD ($)
Assets - money market funds	$ 614,283
Warrant liabilities	0
Embedded conversion option	0
Fair Value, Inputs, Level 1 [Member]
Assets - money market funds	614,283
Warrant liabilities	0
Embedded conversion option	0
Fair Value, Inputs, Level 2 [Member]
Assets - money market funds	0
Warrant liabilities	0
Embedded conversion option	0
Fair Value, Inputs, Level 3 [Member]
Assets - money market funds	0
Warrant liabilities	0
Embedded conversion option	$ 0

Note 13 - Fair Value Measurem70

Note 13 - Fair Value Measurements - Summary of the Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis (Details) - Predecessor [Member] - USD ($)	4 Months Ended	12 Months Ended
	May 04, 2016	Dec. 31, 2015
Embedded Conversion Options [Member]
Balance	$ 0	$ 4,362,225
Established	0	0
Change in Fair Value	0	(4,362,225)
Balance	0	0
Warrant Liabilities [Member]
Balance	0	25,484,596
Established	0	0
Change in Fair Value	0	(25,484,596)
Balance	$ 0	$ 0

Note 14 - Commitments and Con71

Note 14 - Commitments and Contingencies (Details Textual)	4 Months Ended	8 Months Ended	12 Months Ended
	May 04, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2016USD ($)ft²	Dec. 31, 2015USD ($)	Jul. 31, 2009USD ($)
Operating Leases, Rent Expense, Net	$ 87,000	$ 180,000		$ 224,000
Maryland [Member]
Letters of Credit Outstanding, Amount					$ 50,000
Office and Warehouse Facilities in Gaithersburg, Maryland Leases [Member]
Operating Leases, Area | ft²			12,000
Operating Leases of Lessee, Number of Operating Leases			2
Office and Warehouse Facilities in Gaithersburg, Maryland, Lease 1 [Member]
Operating Leases, Monthly Rent Expense			$ 14,000
Office and Warehouse Facilities in Gaithersburg, Maryland, Lease 2 [Member]
Operating Leases, Monthly Rent Expense			$ 4,000
Commercial Operation Facility in Nashville, Tennessee [Member]
Operating Leases, Area | ft²			2,100
Operating Leases, Monthly Rent Expense			$ 4,000
Facility in Durham, North Carolina [Member]
Operating Leases, Area | ft²			16,300
Operating Leases of Lessee, Number of Operating Leases			1
Operating Leases, Monthly Rent Expense			$ 21,000
Sublease of Facility in Durham, North Carolina [Member]
Operating Leases, Sublease Rental Monthly Payments			$ 14,000

Note 14 - Commitments and Con72

Note 14 - Commitments and Contingencies - Future Minimum Lease Payments (Details)	Dec. 31, 2016USD ($)
2,017	$ 463,000
2,018	441,000
2,019	122,000
Total future minimum lease payments	$ 1,026,000